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Abstract 
Introduction: 
 Mild Cognitive Impairment (MCI) is a cognitive stage between normal aging and 
Dementia. It is a heterogeneous group of patients, where most of them develop Alzheimer’s 
disease (AD), others stabilize, and a few revert to normal. AD’s first clinical symptoms are 
related to memory, but it has been shown that AD involves also a processing disorder in the 
visual sensory pathways. Accurate visual function facilitates memory, attention and executive 
functions, so that perceptual dysfunction contributes to the severity of cognitive impairment. 
 
Objective: 
 The objective of the work is to measure changes in activation in the visual system 
between MCI patients and old Healthy Control (HC) subjects, using two different visual 
processing tasks with functional Magnet Resonance Imaging (fMRI). This is the first study 
which makes such a comparison between MCI and HC using fMRI. 
 
Methods: 
 Brain activation was measured using fMRI. The MCI group was composed of 16 
subjects and the HC group was composed of 19 subjects. All subjects performed two tasks: 
location matching (position of objects) and face matching (characteristics of the objects), 
which selectively activate one of the visual system pathways in healthy people. Answers were 
given by pressing a single button. 
 
 
Results: 
 Performance of the task was not significantly different in both groups. The HC group 
selectively activated ventral pathway for face matching and the dorsal pathways for location 
matching. In contrast the MCI subjects did not selectively activate the ventral and dorsal 
pathways of the visual system. Additionally they showed higher activation in the left frontal 
lobe compared to HC when performing the location matching Task 
 
Conclusions: 
 The results suggest that even when behavioural performance between groups is the 
same, the neural system which supports performance may differ. MCI subjects compensate 
their deficits using additional brain areas to help them to maintain performance. In this case 
MCI subjects used the left frontal lobe in addition to perform the location matching task. 
 This work presents the usability of brain imaging techniques especially fMRI to better 
understand the underlying pathology of MCI and its subtypes as prodromal conditions of AD.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Deutsche Übersetzung der Zusammenfassung: 
Hintergrund: 
 Die Leichte Kognitive Störung (LKS) ist ein pathologischer Status zwischen 
„normalem Altern“ und Demenz. In Wirklichkeit ist es eine gemischte Gruppe von Patienten. 
Die meisten dieser Patienten entwickeln eine Demenz vom Alzheimer Typ ,  einige Patienten 
stabilisieren sich und wenige bekommen verlieren ihre kognitive Störung wieder. Die ersten 
Symptome, die bei AD Patienten auftreten, betreffen vorwiegend das Gedächtnis, aber frühere 
Untersuchungen haben gezeigt, dass es ebenso zu Verarbeitungsdefiziten im visuellen System 
kommt. Die visuellen Funktionen sind auch Grundlage für Gedächtnis, Aufmerksamkeit und 
Handlungsfähigkeit, so dass Wahrnehmungsstörungen zur Schwere der kognitiven Störung 
beitragen. 
 
Ziele: 
 Ziel der Arbeit ist der Vergleich der Aktivierungsmuster im visuellen System 
zwischen LKS Patienten und gesunden  Probanden gleichen Alters mittels funktioneller 
Magnetresonanztomographie (fMRT). Das dafür entwickelte Paradigma besteht aus zwei 
visuellen Verarbeitungstestanordnungen Diese Arbeit ist die erste Untersuchung dieser Art 
bei MCI Patienten und gesunden Probanden. 
 
Methoden: 
 Die Messung der Gehirnaktivität erfolgte mittels fMRT. Die Gruppe der Patienten mit  
bestand aus 16 Probanden und die Gruppe der Gesunden bestand aus 19 Probanden. Alle 
Probanden führten zwei Tests aus: „location matching“ (Erkennen der Position von Objekten) 
und „face matching“ (Erkenn der Charakteristika von Objekten). Die gewählten visuellen 
Verarbeitungstests aktivieren selektiv den dorsalen oder ventralen visuellen Pfad bei 
gesunden Probanden. Die Antworten wurden durch Drücken eines Knopfes gegeben. 
 
Ergebnisse: 
 Die Leistung bei beiden Tests zeigte für beide Gruppen  keinen statistisch 
signifikanten Unterschied. Die gesunden Probanden zeigten eine selektive Aktivierung des 
ventralen Pfades für „face matching“ und des dorsalen Pfades für „location matching“. Im 
Gegensatz dazu zeigten die LKS Probanden keine selektive Aktivierung des ventralen oder 
dorsalen Pfades des visuellen Systems. Beim „location matching“ Test zeigten sie erhöhte 
Aktivität im linken frontalen Lappen im Vergleich zu den gesunden Probanden. 
 
Schlussfolgerung: 
 Die Ergebnisse deuten darauf hin, dass trotz nicht signifikant unterschiedlicher 
Leistungen für beide Gruppen, die neuronalen Systeme, die diese Leistungen unterstützen, 
verschieden sein können. Die Patienten mit LKS kompensieren ihre Defizite durch die 
Rekrutierung von zusätzlichen Gehirnarealen, um dadurch ihre Leistung beibehalten zu 
können. In der vorliegenden Untersuchung benutzten Patienten mit LKS zusätzlich den linken 
frontalen Lappen, um den „location matching“ Test zu bewältigen. 
Diese Studie zeigt die Anwendbarkeit von neuroradiologischen Methoden und im besonderen 
von fMRI in der Untersuchung von Demenzen,  um die pathologische Grundlage der LKS 
und ihrer Subtypen als Vorstufen der AD besser zu verstehen. 
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1.  ALZHEIMER’S DISEASE 
 Dementia is characterized by a clinical syndrome of deficits in several aspects of basic 
or complex cognition. The word itself suggests both loss of mind and brain: from Latin, de- 
“down from” or  “out of”, and mens- “mind” or “brain” (Arciniegas B. and Bersford T.P., 
2001). 
 Meta-analyses of studies done in developed countries have established Dementia 
prevalence from around 1% to 5% at the age of 65 years, which doubles every 4 years to 
reach about 30% at 80 years (Ritchie and Lovestone, 2002).  
 Alzheimer’s disease (AD) is the most common cause of Dementia, with 70% 
prevalence. It is a progressive, neurodegenerative disorder characterized by decline of 
cognitive functions. 
 
1.1. Epidemiology: Incidence, Prevalence and Economic Impact 
 The mean age of the population is increasing quickly in the western world because of 
increasing life expectancy and decreasing birth rates. The actual prediction for the number of 
80 year old people in 2050 is about 8 Million in Germany (it was about 3 Million in 2000). 
The highest risk factor for Dementia is age, so that as the mean population age rises, the 
prevalence of new Dementia cases will rise proportionately. It will be necessary, in the near 
future, to consider the public health impact. Care for AD patients is expensive; the mean cost 
of care for an early stage AD patient is now 43,000 Euro per year, advance stage care costs 
92,000 Euro per year. 
 The Rotterdam-Study looked at a population of 7,528 individuals between the ages of 
55 and 106. From this population 474 received the diagnosis of Dementia. The rates at age 
55-59 were about 0.4% and at age 95 and up the rates were 43.2%. Of these 474 cases, 339 
were diagnosed as AD, a rate of 72% (Ott et al., 1995).  The total prevalence in Germany 
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now is between 765,000 – 1.1 Million, but in 20 years it is estimated to increase to about 2 
Million. It can be considered that AD will be the most frequent old age illness in the western 
world. The number of new AD cases in Germany per year is about 115,000 and about two 
third of the patients are over 80 years old (Hampel et al, 2003). 
 
1.2. Pathology  
1.2.1. Neuropathology 
 AD is characterized by the accumulation of insoluble fibrous material, which is not 
randomly distributed, but has a characteristic pattern. The fibrous material is found in the 
form of extracellular amyloid deposits and intraneuronal neurofibrillary changes: 
    a) The extracellular amyloid plaques, or senile plaques, have limited significance for 
differentiation of neuropathological stages. The cerebral cortex, in particular the isocortex, is 
the predilection site for the deposition of amyloid. In early stages there is a big inter-
individual variation of these deposits; but at the end-stage of amiloyd accumulation, there is a 
fairly constant distribution pattern of the pathological material. 
 b) The neurofibrillary changes occur in form of neuritic plaques, neurofibrillary 
tangles (NFT) and neuropil threads (NT). Neuritic plaques vary from one individual to 
another, in opposition with NFT and NT that have a distribution pattern which permits the 
differentiation of six stages (Braak and Braak, 1991):  
• stages I-II (transentorhinal stages): they are characterized by an either mild or 
severe alteration of the transentorhinal region. 
•  stages III-IV (limbic stages): they are marked by an affection of the 
transentorhinal region and entorhinal cortex. Mild involvement of the first 
Ammon’s horn sector. 
•  stages V-VI (isocortical stages): they are marked by the destruction of all 
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isocortical association areas. 
 The main component of the amyloid deposits is the 4.2 kD peptid ß-Amyloid (Aß). 
Each is made of an amyloid nucleus, around which there is a fibrillary amyloid ring. 
 NFT are a pair of  neurofilaments, which are developed in the cell soma and extended 
to dendrites. They are composed of associated microtubular protein 2, ubiquitin, Aß and Tau-
protein. In the NFT of AD patients, we find the hyperphosphorilated form of the Tau-protein 
(Hampel et al, 2003). When cell dies due to these deposits, they revert to “ghost tangles”.  
 NT are agrophilic processes of nerve cells throughout the neuropil. 
 
1.2.2. Changes in neural function 
 We find changes in the neuronal glucose and energy transmission in AD. There is a 
neuronal energy failure and abnormalities in the cellular Ca2+ homeostasis and glucose-
related amino-acid metabolism. It is supposed to occur first at the axodendritic terminals of 
the acetylcholinergic-glutamatergic circuit, causing damage at the synaptic sites (Hoyer, 
1993). 
 
1.2.3. Loss of synaptic connexions 
 Patients with AD have a decreased number of synapses. There is evidence of neural 
plasticity in the AD neuropil; we find that synaptic contact size is increased in patients to 
compensate the loss of synapses. In end stages there is no longer the possibility for 
compensation and  both (synapse number and synaptic contact) are in decline (DeKosky and 
Scheff, 1990). 
 
1.2.4. Neuronal loss 
 Neuronal loss and neurofibrillary tangles increase in parallel with the duration and 
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severity of illness. In contrast there is no correlation between the number of senile plaques, 
amount of neural loss, and the number of neurofibrillary tangles and duration of disease 
(Gomez-Isla et al., 1997). 
 Cortical cholinergic denervation is due to cytoskeletal pathology. But in a few areas, 
such as the cingulated cortex, the cholinergic fiber loss seems to be unrelated with the density 
of tangles  (Geula et al., 1998). 
 
1.2.5. Neurodegeneration process in different brain regions 
 Only a few neuronal types are altered in AD. Cytoskeletal alterations occur first in 
form of neurofibrillary tangles and neuropil threads in the allocortex. These lesions have a 
predictable sequence of appearance in other territories of the cerebral cortex and subcortical 
nuclei. Some components of the brain are devastated while other parts remain intact until the 
end phase of the disease. At the beginning of the degenerative process the illness remains 
subclinical for years. By the time clinical symptoms appear, neocortical association areas are 
usually already affected. The destruction seems to have an inverse sequence relative to 
cortical myelination; the last myelinated areas are affected first (Braak et al., 1999). 
 AD pathology results from the disruption of cortical circuitry; it produces the halt of 
communication between some cortical areas, with anatomic isolation and fragmentation of 
many cortical zones. But not all circuits are equally vulnerable to AD pathology; two cortical 
systems that are involved in the neural processing of memory are selectively affected. The 
first consists of the connexions between the hippocampus and its neighbouring cortical 
structures within the temporal lobe. The second is the cortical cholinergic system that 
originates in neurons within the basal forebrain and innervates the entire cortical mantel. The 
selective vulnerability of  these circuits is the probable reason for the early marked loss of 
memory observed in these patients (Geula, 1998). 
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 AD is a disease of the cerebral cortex and the subcortical nuclei which innervate it; the 
primary target of the disease is the cerebral cortex and the interconnected subcortical nuclei 
are secondarily affected (German et al., 1987). 
 
1.2.6. Neurochemical changes 
One of the most important modulatory neurotransmitter systems in the brain is the 
cholinergic system. It controls activities that depend on selective attention (an essential 
component of conscious awareness) (Perry et al., 1999). In AD the most significant change is 
the loss of cortical cholinergic markers. There is a loss of choline acetyltransferase (ChAT) 
activity. The severity of Dementia and the numbers of neurofibrillary tangles are correlated 
with the reduction in the ChAT activity (DeKosky et al., 1992; Wilcock et al., 1982). The 
most affected cortical areas of the brain are the temporal association areas, but the anterior 
cingulate cortex, primary visual, primary somatosensory, and primary motor cortex are 
relatively preserved at the beginning (Geula and Mesulam, 1996). 
 
1.3. Cognitive changes 
 The symptoms begin gradually. The pattern of symptom appearance is correlated with 
the anatomic neuronal degeneration, and the pathological processes of AD. For example the 
building of NFT, affect the cortical association areas (frontal, temporal, parietal, and limbic 
lobes) as well as the linkages among them. The earliest changes occur in the enthorhinal 
cortex and hippocampus, with pathology progression in the other areas (Braak and Braak, 
1991).  
 Due to the early neurodegenerative effects on the hippocampus, we can find short-
term memory impairment as the first sign of the disease, such as memory process and  recall 
from new information (Petersen et al., 1994).  
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 The symptoms begin creeping and slowly progress, often they appear together with 
depressive symptoms together. The cognitive impairment increases with the course of the 
illness. Episodic and semantic memory as well as temporal and spatial orientation, are 
affected in the progression of the disease (Bondi et al., 2005). Later there is a deficit in long-
term memory as well, but experiences from the childhood remain the longest in memory 
(Sagar et al., 1988), and patients lose their ability to manage their activities of daily living, so 
that the complete care of the patients needs to be provided by others.  
 
1.4. Risk Factors 
 The most important risk factor for AD is age. In addition other risk factors have been 
identified: female gender, apolipoprotein ε4 allele, low serum levels of folate and vitamin 
B12, elevated plasma and total homocysteine levels, smoking, family history of AD or 
Dementia, fewer years of formal education, lower income, and lower occupational status 
(Launer et al., 1999). 
 Education and occupational status: there is a diversity of opinion about the role of 
education and occupational status as a risk factor for AD. Some studies show that lower 
education and lack of occupation are risk factors (Mortel et al., 1995; 1994; 2003; Ott et al., 
1995). But other studies do not confirm this theory (Beard et al., 1992; Fratiglioni, 1996). 
The results of the EURODEM Group were that the association between low education and 
risk for AD could only be shown in women (Letenneur et al., 2000; Fratiglioni, 1996).  
However some studies found that low education level can increase the risk of non-AD 
Dementia (Cobb et al., 1995; Bickel and Cooper, 1994). 
 Genetic: We can differentiate two genetic groups for the apparition of AD: the first 
represents 90% of the cases and occur sporadically. The second group is hereditary and 
represents the remaining 10% of the cases. It is called the familial form of AD (Haass and 
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Baumeister, 1998). The relative risk of AD for people with family history (at least one first 
degree relative with Dementia) is 3.5 times higher. For those with two or more affected 
relatives the risk is 7.5 times higher. 
 Head traumatic injury: In the study performed by Mortimer et al., a re-analysis of the 
data from 11 case-control studies was performed to investigate the association between head 
trauma and AD (Mortimer et al., 1991). The findings of the analysis support an association 
between reported head trauma and AD. But the EURODERM-study, contrary to previous 
reports, found that head trauma was not a risk factor for AD (Launer et al., 1999). In this 
study the association between the risk of AD and some factors like gender, head trauma etc 
was investigated. The authors performed a pool analysis of four European population-based 
prospective studies of individuals of 65 years and older, with 528 incipient Dementia 
patients. 
 Gender: The studies of prevalence like the EURODEM-study showed that for women 
incidence rates of AD are higher than for men (Launer et al., 1999). 
  
1.5. Clinical Diagnosis 
 AD is characterized by a long preclinical period during which cognitive deficits are 
detectable. At the beginning, symptom apparition progresses slowly. The pattern of symptom 
apparition is correlated with the anatomic neuronal degeneration: the earliest changes occur 
in the enthorhinal cortex and hippocampus with development of neurofibrillary tangles; the 
accumulation of ß-amyloid occurs in neocortex (Braak and Braak, 1991), so that  we almost 
always find short term memory impairment as the first sign of the disease (Petersen et al., 
1994).  Later on the temporal and parietal lobes suffer pathological changes as well, so that 
language and visuoconstructive deficits appear. 
 Patients suffering from mild AD also show impairment in long-term memory. 
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Memory of personal and public events from the distant past is less affected than recent 
memory in the early stages of disease. But the magnitude of the retrograde loss is related to 
severity of Dementia (Sagar et al., 1988). Patients are severely affected in the activities of 
daily living when orientation problems appear.  
 A detailed description of clinically relevant topics of the illness and its evolution can 
be assessed through the severity levels or stages of the illness. These “stratified severity 
levels” or stages are considered as clinical estimations of the evolution of the disease. Within 
the context of AD there are a variety of clinical severity rating scales. One of the more widely 
used is the Mini-Mental State Exam (MMSE), but the scores of this test do not give a full 
comprehensive picture of the patient’s clinical status. It is necessary to have a global scale, 
including ratings for deficits in all areas considered to be essential for the clinical diagnosis 
of AD. The Global Deterioration Scale (GDS) (Reisberg et al., 1982) is a global measure for 
the assessment of cognitive decline secondary to normal aging and also AD. It is based on the 
patient’s status encompassing the areas of cognitive, functional (for example activities of 
daily living) and behavioural pathology. 
 Another battery of test very useful in the diagnosis of AD is called CERAD 
(Consortium to Establish a Registry for Alzheimer’s disease). It was developed to provide a  
brief, comprehensive, and reliable battery of clinical and neuropsychological tests for the 
assessment of patients with the clinical diagnosis of  AD (Morris et al., 1989b; Morris et al., 
1988). 
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2. MILD COGNITIVE IMPAIRMENT AND COGNITIVE DECLINE  
 Mild Cognitive Impairment (MCI) has received a considerable amount of interest in 
recent years.  In fact in the development of the characterization of the clinical diagnosis 
related to AD and Dementia, the definition of MCI has been changing. Formerly, Mild 
Cognitive Impairment was thought to be part of the normal process of aging. MCI is now 
understood to be a diagnosable pathology (as distinct from normal aging). With new 
diagnostic criteria the number of old people understood to be suffering from some kind of 
pathological cognitive impairment has increased. In addition, MCI has been considered as a 
possible prodromal phase of AD and other types of Dementia, a transitional state between 
normal aging and AD. 
 Normal “healthy” aging means aging without disease. Aging is a major risk factor for 
developing Dementia, but does not necessarily lead to age-related diseases. Many old people 
do not have symptoms of disease and live normal lives. Early pathological disease-related 
changes constitute the beginning of Dementia rather than the normal concomitants of aging, 
even in the absence of any clinical symptoms (Thal et al., 2004) . 
 The prevalence of MCI is about 16-34% (Devanand et al., 1997).  Some studies show 
that 2-3 years after diagnosis, 70% of MCI patients have developed Dementia (Dartigues et 
al., 1997). 
 In people who are destined to develop AD, there is a progressive decline in cognitive 
function. The criteria for clinically probable AD are defined by the symptoms of people who 
already have a substantial degree of cognitive decline. The condition of MCI makes it 
possible to identify these individuals at an earlier point in the cognitive decline. The 
recognition of MCI as a pathological condition and not a manifestation of normal aging has 
received attention as a clinically useful entity (Petersen, 2004).  
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2.1. Outcome 
 Using the Mayo criteria (see 2.2.), the progression from MCI to Dementia is 
considered to be about 12% per year, while the progression from normal cognition to 
Dementia is about 1-2% per year (Petersen, 2000). But there is some diversity in rates of 
progression between authors due to differences in the definition of the patient groups, and 
different implementation of criteria and length of follow up in the studies. 
 To unify this criteria it is very important to use appropriate and sensitive 
neuropsychological and functional measures to diagnose MCI and to use reliable methods to 
determine progression or improvement of cognitive impairment (Luis et al., 2003). 
  
2.2. Clinical Characterization 
 There is no agreement on the diagnostic criteria of MCI. In general these individuals 
have some cognitive impairment (they can be differentiated from healthy people) but not 
enough to fulfil the criteria of Dementia (Petersen et al., 1999).  
 The Mayo Alzheimer’s Disease Research Center has had some original diagnostic 
criteria focused on the memory impairment: memory complaint (preferably corroborated by 
an informant), objective memory impairment for age, relatively preserved general cognition 
for age, intact activities of daily living and lack of Dementia (Petersen et al., 1999). But these 
criteria have been modified in recent years, as it is known that other cognitive domains are 
also impaired in some types of MCI. 
 Clinical subtypes of MCI have been proposed. All individuals who show symptoms of 
MCI may not have the same development. Some of them develop AD, while others progress 
to other types of Dementia. There are also some individuals who will never progress to any 
type of Dementia. Due to the heterogeneousness of this disease it is proposed that there are 
several subtypes of MCI (Petersen et al., 2001). Clinical trials have been used with some 
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inclusion and exclusion criteria to make the definitions of the subtypes of MCI. A consensus 
conference in 2001 proposed three subsets of MCI (see Table 1):  
-MCI Amnestic (a-MCI): it is the most common form of MCI, and it is thought to be a 
forerunner of AD. This characterization agrees with the original Mayo criteria for MCI. 
-MCI Multiple domain (md-MCI): involves impairment in different cognitive domains such 
as language, visuospatial skills with or without memory impairment (amnesia), so that we 
have: 
  -md-MCI + a: possibly a forerunner of AD and Vascular Dementia (VD) 
  -md-MCI – a: possibly a forerunner of Vascular Dementia and Dementia with 
              Lewy Bodies (DLB) 
-MCI single nonmemory domain: presents impairment in one single domain other than 
memory. This subtype could be the forerunner of Frontotemporal Dementia (FTD) and 
Dementia with Lewy bodies (DLB).  
 In addition to these subtypes, there can also be multiple aetiologies or causes for each 
subtype. The combination of clinical subtypes and putative aetiologies can be useful in 
predicting the ultimate type of Dementia.  
 
2.3. Amnestic MCI 
The criteria necessary to meet the diagnosis of a-MCI are: 
 -Memory complaint usually corroborated by an informant: this is a ‘soft’ criterion and 
it is meant to capture the notion of a change in performance, because it represents a change in 
function for the person.  
 -Objective memory impairment for age: it can be identified with neuropsychological 
testing, but there is still no agreement about the scores which determine the pathology. It is 
necessary to make a precise history from the patient to note if his level of performance is 
 12 
really impaired in comparison with his intellectual level. 
 -Essentially preserved general cognitive function: it refers to the other nonmemory 
domains. 
 -Largely intact functional activities: this information should be obtained from the 
patient and informant. There are often some deficits in daily function because of the memory 
problems, but this is not considered to constitute a major disability. 
 -Not demented: this must be judged by the clinician with the results of the other four 
criteria. In general MCI subjects appear more normal than not. The difficult distinction is 
between normal aging and MCI rather than between MCI and AD. 
 
2.4. Biological Basis of Cognitive Deficits due to MCI  
 Impairment in multiple cognitive domains several years before the clinical diagnosis 
is characteristic for AD. Many brain structures and functions are affected even before 
symptoms appear, such as the Medial Temporal Lobe (MTL). MLT atrophy is linked to loss 
of episodic memory (Backman et al., 2004). Episodic memory is not a unique status among 
cognitive measures in differentiating those who will develop AD versus those who will not. 
To better understand the pathological aspects of the preclinical state of AD, it is possible to 
relate the cognitive systems breakdown to the brain structures affected: 
-volume reduction of anterior cingulate and temporal sulcus, posterior cingulate and 
neocortical temporoparietal regions and frontal regions 
-decreased blood flow in posterior cingulate and precuneus 
-reduced glucose metabolism in temporoparietal regions 
-deposits of amyloid plaques in the temporal and frontal cortex 
-increase of white matter hyperintensities 
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2.5. Biomarkers 
 In the MCI stage there are no clinical methods to determine which patients will 
progress to AD, except for a very long clinical follow up. And there is a great clinical need 
for diagnostic instruments to identify incipient AD (Blennow, 2004). 
 There is currently no agreement on the best biomarker for early diagnosis of AD. 
There are two choices as most potentially useful biomarkers (de Leon et al., 2004): magnetic 
resonance imaging (MRI) and Cerebro-spinal fluid (CSF) studies. But these biomarkers also 
present problems: 
-MRI volume changes are not specific for AD and require intensive skilled labour 
-The measurement of total T-tau level and amyloid ß42 are not really specific for AD and do 
not change with disease progression 
-Aß42 levels are not easily interpreted because production and clearance are not well 
characterized 
-CSF acquisition is invasive 
 
2.6. Onset of precipitous decline 
 Cognitive decline may not be expected until some biological events (e.g. the 
accumulation of amyloid and neurofibrillary tangles, inflammation, oxidative stress, loss of 
synapses, death of neurons) have reached a certain threshold. Until this moment the brain is 
able to compensate for the pathological changes of AD.  
 There are individual differences with regard to onset and rate of change in preclinical 
AD, some have a very fast decline before diagnosis, and others show gradual decline over a 
longer period.  
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2.7. Recommendations for the general criteria for MCI: 
 -Not normal, not demented (does not meet DSM IV and ICD 10 criteria for a 
Dementia syndrome) 
 -Cognitive Decline 
 -Self and/or informant report of impairment on objective cognitive tasks 
 and/or 
 -Evidence of decline over time on objective cognitive tasks 
 -Preserved basic activities of daily living / minimal impairment in complex 
instrumental functions. 
 Future research should focus on identifying the prevalence of the three clinical 
presentations of MCI and also to establish the aetiology behind the impairment, both with 
clinical data and population based studies (Winblad et al., 2004). 
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Table 1. Clinical subtypes of mild cognitive impairment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
   AD- Alzheimer’s disease 
    Depr- Depression 
    VaD- Vascular Dementia 
    DLB- Dementia with Lewy Bodies 
  FTD- Frontotemporal Dementia 
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[Petersen et al. 1999]
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3. THE ROLE OF NEUROIMAGING IN MCI AND AD 
 In the recent past, neuroimaging has come to play an important role in the diagnosis of 
Dementias. Dementia is a growing social problem and the development and advancing of 
neuroimaging provides the necessary means for rigorous and early diagnosis. This is 
particularly true in light of new therapeutical research, which points to new therapies that will 
be more effective in preventing or slowing disease progression (Bastos Leite et al., 2004).  
 In the pathological process of Dementia, patients suffer anatomical brain changes. 
Even in healthy individuals, after the fifth decade of life, we find some changes in brain 
anatomy, such as reductions in brain weight (Dekaban, 1978).  The American Academy of 
Neurology has published the practice parameters for the diagnosis of Dementia, and in the 
current standards of clinical practice the use of neuroimaging in the diagnosis and treatment 
of AD is not required. But the present knowledge about this disease allows physicians to use 
neuroimaging as a supporting tool in the early diagnosis of AD or in the differential diagnosis 
to distinguish AD from other pathologies. It is a tool which assists the clinicians to examine 
structural, functional and biochemical changes in the brain. These methods include: Structural 
imaging like Magnetic Resonance Imaging (MRI) and Computer Tomography (CT); and 
functional imaging like functional Magnetic Resonance Imaging (fMRI), Positron Emission 
Tomography (PET) and Single Photon Emission Computed Tomography (SPECT).  
 A study by Chui and Zhang revealed that the use of structural imaging and PET 
improves the diagnosis of Dementia. In fact the clinical diagnosis changed for 19% of the 
patients and the clinical management for 15% of the patients, with the conclusion that the 
clinical evaluation was unable to predict neuroimaging findings (Chui and Zhang, 1997).  
Some other authors like Small et al. found that functional neuroimaging can be useful 
predicting evolution of disease and also following disease progression in people at risk for 
AD  (Small, 2002). 
 In relation to structural imaging, except in cases where MRI is contraindicated or not 
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available, there is no reason to prefer CT over MR as an anatomical screening method for 
Dementia (Petrella et al., 2003). 
 The clinical course of Dementia begins years before symptoms appear.  Functional 
neuroimaging should be a very useful method for early diagnosis, because it allows the 
investigation of nerve cell dysfunction (Haxby et al., 1987) 
 We see some areas of hypometabolism in AD patients before symptoms appear 
(Johnson et al., 1998; de Leon et al., 2001; Okamura et al., 2002; Chetelat et al., 2003) . 
Techniques like PET or SPECT, therefore, have the advantage of showing these brain 
metabolic changes that precede structural brain changes. 
 It has been thought that MCI is a transitional state between normal aging and AD. It is 
in fact a kind of catch-all for symptoms that by traditional diagnostic methods can be 
misunderstood. It represents a heterogeneous group of patients, where some of them develop 
Dementia or AD, others stabilize, while others revert to normal (Petrella et al., 2003). 
Functional neuroimaging studies are underway to identify converters from MCI to AD, and 
also from normal aging to MCI (Johnson et al., 1998; de Leon et al., 2001; Okamura et al., 
2002; Chetelat et al., 2003).  
For example in the study by Linn et al. the interval between the onset of detectable 
cognitive impairment and clinical diagnosis in individuals with probable AD (Linn et al., 
1995) was evaluated, and they tried to identify the pattern of the earliest changes in cognition 
in probable AD. Their findings support previous contentions that a "preclinical phase" of 
detectable cognitive deficits can precede the clinical diagnosis of probable AD. But the 
question is, how do we reach the most precise and earliest diagnosis. Dysfunctions in people 
at risk for developing AD may be identified with fMRI years before symptoms appear. By 
means of fMRI, compensatory strategies developed from people at risk for AD 
(Apolipoprotein genotype epsilon 4, APOE) can be shown. Before symptoms appear at all, 
these people require additional cognitive effort to perform tests in comparison to people 
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without risk (Bondi et al., 2005).  
Although there are not so many studies using fMRI to investigate early deficits from 
patients which may develop AD, it has been shown that fMRI plays a promising role in the 
preclinical characterization and very early diagnosis of AD (Fleisher et al., 2005). Therefore 
studies using fMRI need to be extended to the MCI group to further characterize this group of 
patients and their deficits and to differentiate the MCI patients developing AD from those 
developing other types of Dementia. An additional benefit of early diagnosis of AD would be 
higher effectiveness of the currently available treatment options for AD, as it is believed that 
the available treatment options would be more effective the earlier they would be given to the 
patients, as the disease process has not led to extensive neuronal and synaptic dysfunction in 
large areas of the brain. 
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4. FUNCTIONAL IMAGING 
4.1. Neuroimaging of cognitive functions in the human brain: Brain Mapping 
 The fact that there is a localization of function in the human brain has long been 
known.  It was proved by the cortical stimulation of patients during neurosurgery, in the 
middle of the 20th century (Savoy, 2001). The disadvantage of these studies was the fact that 
pathological brains were studied and not healthy ones. During the second half of the 20th 
century the exploration of cognitive functions in human brains was advanced by means of 
neuroimaging.  Before neuroimaging was established as an exploration method of the brain, 
almost the whole knowledge of cognitive functions was first obtained from the exploration of 
patients through neuropsychological methods. And more information was gained later 
concerning the relationship between different neurostructures, when primates were included 
in these studies (Krause and Müller-Gärtner, 2005).  
 The goal of functional neuroimaging is to map the activity of the living brain in space 
and time.  It intends to explore normal and pathological living brains with a non-invasive 
method. It allows the identification of the functional neuroanatomy of different cognitive 
functions and to measure how the different brain areas work together by the executions of 
cognitive exercises. This new field of research is often termed “Brain Mapping”.   
 There are two different approaches of non-invasive functional neuroimaging: 
• electrophysiological methods, such as electroencephalography (EEG) and 
magnetoencephalography (MEG), measure signals which arise as the sum of electrical and 
magnetic events in individual cells. The main advantage of these methods is their temporal 
resolution. The main disadvantage is that they rely on sensors located outside of the brain, so 
that they provide ambiguous spatial information. This information is not sufficient for 
creating accurate images of function. 
• metabolic/vascular methods, such as positron emission tomography (PET) 
and functional magnetic resonance imaging (fMRI). These approaches are more indirect 
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because they measure metabolic correlates of neuronal activity, but not activity itself. FMRI 
measures blood oxygenation level, which changes with the metabolic demands of active 
neurons. The technique that forms the basis for nearly all fMRI studies is blood-oxygenation-
level dependent (BOLD) contrast. The metabolic/vascular methods have very good spatial 
resolution, good delineation of the spatial extent of an activated area and precise matching to 
anatomical structures. 
 
4.1.1. Physiological changes during brain activation: 
 The fundamental element for the processing of information in the brain is the neuron, 
which has two primary roles, integration and signalling. Changes in cell membrane potential 
and release of neurotransmitters are the basis for the activity of neurons. These functions are 
made possible by the movements of ions across neural membranes. The restoration of 
concentration gradients following neuronal activities requires an energy supply. This energy 
supply comes from the molecule ATP. The process of formation of the ATP molecule 
requires glucose and oxygen consumption. These metabolites are supplied by the vascular 
system. 
 Changes in the vascular system may occur in response to neural activity. Roy and 
Sherrington postulated that the increase in neural activity in one region also means an increase 
in cerebral blood flow and oxidative metabolism (Friedland and Iadecola, 1991).  The 
regional cerebral blood flow (rCBF) increase brings glucose and oxygen to the activated brain 
areas. That is the physiological basis of fMRI and PET (see Table 2). 
 
-Translation of Brain Activity into a Functional image: 
 To understand how functional images are obtained with these methods, it is important 
to know: 
 -the relationship between local brain activity and the physiological parameters which 
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are measured 
 -the relationship between these physiological parameters and the obtained functional 
image. 
 Brain activity can be mapped in two ways, metabolic and vascular, creating two kinds 
of functional images (Moonen and Bandettini, 2000). This can be represented:  
Brain Activity   →   Metabolic Response   →   Functional Image 
  f(x,t)                         g(f(x,t))                                h(g(f(x,t))) 
  
Brain Activity   →   Vascular Response   →   Functional Image 
  f(x,t)                         i(f(x,t))                                 k(i(f(x,t))) 
 
where: x means location, t means time, f(x,t) means functional convolution of brain cell 
activity, g(f(x,t)) means change in metabolism and i(f(x,t)) means change in Cerebral Blood 
Flow (CBF) or neurovascular coupling. 
 We obtain maps of metabolic [h(g(f(x,t)))] and vascular [k(i(f(x,t)))] events associated 
with changes in brain activity. At this point there is always a loss of information which occurs 
on at least three levels: 
 -qualitative reduction of many different types of brain cell activity into just one 
dimension of brain activity: increase of cerebral blood flow and local cerebral glucose 
utilization reflects different facets of brain activity like synaptic and presynaptic activity 
(excitation / inhibition), action potential of the neuron soma and subthreshold depolarization. 
But more than 85% of cerebral glucose is used in the presynaptic axon terminal of neurons  
(Jueptner and Weiller, 1995). This means that the maps of metabolism and blood flow are 
principally ambiguous with respect to the underlying neurophysiological event. 
 -a loss of spatial resolution: it is possible that the spatial error for the vascular response 
is quite significant, because the spatial relationship to brain activity is given by the smallest 
theoretically possible functional unit in the vascular system. This is probably a single 
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capillary. Some authors say that the opening and closing of capillaries produces changes in 
capillary blood volume, and this should represent a major mechanism of blood flow 
adjustment in the brain (capillary recruitment hypothesis) (Shockley and LaManna, 1988). 
Although this question is not definitely clear, there seems to be no convincing argument that 
the smallest functional unit of vascular regulation in the brain is in fact the feeding arteriole. 
 -a loss of temporal resolution: neuronal events occur on a time scale of milliseconds 
and vascular events occur on a time scale of seconds. This sets limits on the temporal 
resolution of functional neuroimaging approaches based on metabolic/vascular imaging. 
 
4.2. Functional MRI 
4.2.1. MRI principles 
 Magnetic Resonance Imaging (MRI) is a non-invasive technology for creating pictures 
of the soft tissues of the human body. MRI is useful in Neuroscience for the study of multiple 
brain tissues related to brain anatomy and has two very important benefits: 
1) The images have high spatial resolution and contrast. 
2) The technology does not use ionizing radiation. It is a tool that can be used safely and 
repeatedly on adult and children volunteers, as well as patients. 
 The physical principle underlying MRI is nuclear magnetic resonance (NMR).  It 
permits the detection of the hydrogen nuclei of water molecules in the body by their 
interaction with a magnetic field. Hydrogen nuclei have an odd number of nucleons (protons 
+ neutrons) so that they posses a magnetic moment and a spin (angular momentum). In the 
presence of an external magnetic field these particles  reorganize themselves and  spin with a 
movement called precessing. Some of them go to the position requiring the least energy. In 
this position their magnetic moments are parallel to the external field. Other particles precess 
with a magnetic moment which is antiparallel to the external field, the position requiring high 
energy.  The rate of precession is proportional to the local magnetic field strength. 
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 Excitation of the hydrogen nuclei can be reached by the application of a pulse of 
magnetic energy at the resonant frequency of the precession. Some of the low energy nuclei 
absorb energy from the pulse and will change to a high energy state. After the energy source 
is removed the nuclei return to the low energy position and give off the absorbed energy. 
Measurement of this emitted energy (NMR signal) provides the data which create the images. 
 The application of the pulse of magnetic energy (rf-pulse) makes hydrogen nuclei 
change orientation. If we control the power and duration of the rf-pulses we can change the 
main magnetization vector by an angle θ, called the flip angle. This angle can be 45°, 90° or 
180° away from the least energy position.  
 By systematically varying the strength of the externally applied magnetic field across 
the three dimensions of space, and measuring the NMR signal as this is done, it is possible to 
generate images based on the differences of NMR signals at each point in space.  MRI allows 
us to see differences in the physical properties of tissues. 
 
 
4.2.2. Physiological basis of Blood-oxygenation-level dependent (BOLD) fMRI: What 
does fMRI tell us about neural activity? 
 It is also possible to obtain functional images of the brain under the influence of a 
magnetic field by measuring blood flow and changes in blood characteristics in the brain. The 
most common functional MRI technique is the BOLD-fMRI (Blood-Oxygenation-Level-
Dependent fMRI). It is based on the different magnetic properties of deoxy- and oxy-
haemoglobin, and also on the coupling of oxygenated blood flow and neuronal activity. It 
does create images of physiological activity that is correlated with neural activity. 
 The work of the American chemist and Nobel Laureate Linus Pauling and his student 
Charles Coryell showed in 1936 that the magnetic properties of the haemoglobin molecule are 
different depending on whether or not it is bound to oxygen. Oxygenated haemoglobin is 
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diamagnetic (zero magnetic moment) and deoxygenated haemoglobin is paramagnetic 
(significant magnetic moment).  
 In the early 1980s Thulborn and colleagues found that the decay of transverse 
magnetization is dependent on the proportion of oxygenated haemoglobin within a test tube of 
blood (Thulborn et al., 1982). These results provided a theoretical basis for the measurement 
of blood oxygenation changes using MRI. In the late 1980s Seiji Ogawa investigated  the 
possibility of examining brain physiology using MRI techniques. Based on the previous 
findings that deoxyhaemoglobin decreases the T2* weighted value of blood, Ogawa and his 
colleagues made some experiments using both test tube and animal models. Their findings 
showed that the blood-oxygenated-level dependent (BOLD) contrast could enable 
measurement of functional changes in the brain, because the BOLD contrast was found to 
depend upon the total amount of deoxygenated haemoglobin present in a brain region, which 
in turn depended upon oxygen consumption and oxygen supply (Ogawa et al., 1992; Ogawa 
et al., 1993). 
 
The coupling of Oxygen comsumption and Blood Flow 
 Fox and Raichle (Fox and Raichle, 1986) postulated that there exists a disparity 
between oxygen consumption and oxygen delivery in an activated brain; more oxygen is 
supplied to the brain than is consumed. This is due to an increase in the velocity in the 
cerebral blood flow. The capability of the capillary system to deliver oxygen to tissue is less 
when the transit time decreases. It means that in the venous system (after the oxygen 
exchange has been done) the oxygen concentration is higher than before neural activity in one 
region started. 
 BOLD contrast following neuronal activity occurs not because oxygenated 
haemoglobin increases in the NMR signal but because it displaces the deoxyhaemoglobin. 
Neuronal activation produces local hemodynamic changes, as Roy and Sherringtong 
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postulated. It means that there is an increase in local blood flow and local blood volume. But 
there is relatively little change in oxygen consumption, so oxygen concentration in venous 
blood increases, and deoxy haemoglobin concentration decreases. This effect can be measured 
in the scanner because there is less magnetic substance in the venous blood and the signal 
increases on T2* weighted images. 
 
Components of the BOLD Hemodynamic Response 
 The change in the NMR signal triggered by neuronal activity is known as the 
hemodynamic response (HDR). Cortical neuronal responses occur within tens of milliseconds 
following a sensory stimulus, but the first observable HDR first occurs 1 to 2 seconds later. 
BOLD signal in a voxel reflects the amount of deoxyhaemoglobin (which is contained in the 
voxel) and also noise, coming from different sources.  It is known that there is an initial dip of 
1 to 2 sec. in the signal, which is attributed to the transient increase in oxyhaemoglobin in 
blood flow at the beginning of the neuronal activity increase.  After this 2 sec., the signal 
increases up to a maximum value (peak of the hemodynamic response) at about 5 sec., for a 
short duration. But if the neuronal activity is extended across a block of time, the peak may be 
similarly extended onto a plateau.  After reaching this peak, the BOLD signal decreases to a 
below-baseline level (undershoot) and remains so for an interval of time. 
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Table 2. Changes in cell metabolism and blood flow during functional activation 
 
BRAIN ACTIVITY
↑ ENERGY REQUIRMENTS
SIGNAL IS SENT TO THE
FEEDING ARTERIOLE
↑ OXYGEN CONSUMPTION
↑ CBF IN DOWNSTREAM
CAPILLARIES
↑ [deoxy-Hb]
(Presynaptic activity)
(oxidative Glucose 
consumption)
(Dilatation)
(During resting conditions all
capillaries are already perfused,
but the blood flow per capillary
increases and
heterogeneousness of blood
decreases)
(Basis of the BOLD 
contrast in fMRI)
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5. VISUAL SYSTEM 
5.1. Anatomy of the visual system 
 Vision provides the largest part of the sensory information we receive from our 
environment. Vision occurs when light falls on the retina where it is transformed into 
electrical potentials which are transmitted via Thalamus (Lateral Geniculate Nucleus) to the 
Cerebral Cortex.   
 The Lateral Geniculate Nucleus (LGN) is composed of six layers: two of which have a 
ventral localization and are composed of big neurons. They are called magnocellular neurons.  
The rest are in a dorsal localization and are little neurons, they are called parvocellular 
neurons. They have different functions in the visual system. Both of them send their axons to 
the primary visual cortex in the Calcarine Fissure (Brodmann area 17), which integrate the 
Radiatio Optica. The magnocellular neurons are the part of the visual system which process 
location and movement information of objects. Color and shape information of objects are 
processed by parvocellular neurons. The neurons in the LGN send their axons directly to V1 
(primary visual cortex, striate cortex, area17) via the optic radiations.  This highway of visual 
information courses through the white matter of the temporal and parietal lobes. 
 The primary visual cortex, V1, is located around the Calcarine Fissure in the occipital 
lobe. It is the best studied visual area of the brain. It is the part of the visual cortex that is 
responsible for processing visual stimuli. The primary visual cortex is divided into six 
functionally distinct layers, labeled 1 through 6. Layer 4 receives most visual input from the 
LNG. 
 There are three more association visual areas: the V2, V3 and MT (V5). V2 is the 
second major area in the visual cortex, and first region within the visual association area. It 
receives strong feedforward connections from V1 and sends strong connections to V3, V4 and 
V5,  and also strong feedback conexions to  the V1.  
 The multiple visual cortical areas are organized into processing streams. According to 
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the model originally proposed by Ungerleider and Mishkin 1982 (Ungerleider and Mishkin, 
1982), there are two major processing streams. The origin of both of them is the primary 
visual cortex (striate cortex), V1. Both of them consist of different visual areas beyond the V1 
(extrastriate areas). The ventral stream goes through visual area V4 into the temporal lobe and 
is responsible for visual recognition of objects. The dorsal stream goes through visual areas 
V2, V3 and MT into the parietal lobe and is responsible for the spatial relationships of the 
objects (see Figure 1). It can be expressed in terms of “what versus where” (Ungerleider and 
Haxby, 1994; Ungerleider and Desimone, 1986a; Ungerleider and Desimone, 1986b). 
 
The Ventral Stream 
 The visual information impinging on the retina is a two dimensional projection of a 
three dimensional world. This projection varies in order to the position, distance, illumination, 
and orientation relative to the viewer. The function of the ventral stream can be described as 
determining and encoding these features which are so important for the object recognition. 
The neurons which compound the ventral stream have sensitivity to the shape, color or texture 
of visual stimuli, it is a parvocellullar dominated stream.  In the progression along the 
pathway, the neurons can process more complex stimulus features or combination of features. 
 
The Dorsal Stream 
 One of the more prominent features of the neurons in the dorsal stream is selectivity 
for the direction of visual motion. But the properties like sensitivity to binocular disparity and 
the property believed to underlie depth perception are characteristic of many neurons in the 
dorsal stream. And many properties of these neurons point to their role in the processing of 
location information in active observers. It is a magnocellular dominated stream. 
Beyond Visual Processing Streams 
 In order to execute visually guided behaviours successfully, the information carried by 
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the two streams must be integrated. It seems that some kind of integration occurs within the 
stream, but this is only partial. The question where this definitely integration occurs is already 
not answered, but it must be in areas outside of the visual system.  
 Some studies have shown that projections from areas in the dorsal stream terminate 
mainly in and around Brodmann area (BA) 46 of dorsolateral prefrontal cortex (Ungerleider 
and Desimone, 1986b). The projections from the ventral stream terminate mainly in the BA 
12 and 45 of ventrolateral prefrontal cortex (Ungerleider et al., 1989). Although the inputs to 
prefrontal cortex from the two streams are anatomically segregated, there is evidence of the 
existence of individual prefrontal neurons that process information about an object’s identity 
and its location (Rao et al., 1997),  in this way this information may be integrated. 
 In studies in which diverse cognitive demands were performed (like response conflict, 
task novelty, working memory or perceptual difficulty), it was shown that there are three 
common regions which are always activated, mid-dorsolateral, mid-ventrolateral, extending 
along the frontal operculum to the anterior insula and  the dorsal part of the anterior 
cingulated (Duncan and Owen, 2000). This common network of active regions seems to be 
activated in demands as diverse as response selection, working memory maintenance and 
stimulus recognition. 
 
5.2. Visual Attention and Perception 
 Attention is a critical determinant of what we perceive. It makes the difference 
between looking and seeing. It may alter the cortical representation of the visual scene in a 
way that is equivalent to increasing the contrast of those stimuli that currently have 
behavioural relevance. 
 Since the mid-70s experiments have demonstrated that the organization patterns of 
neurons in primary visual cortex are not genetically fixed, but develop from visual 
experience. Connexions among neurons are initially more or less randomly scattered. With 
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visual experience, the neurons appear to divide their work: some neurons reinforce each other 
and some unnecessary connexions are eliminated. Such filtering allows the brain to efficiently 
process the massive amounts of visual information impinging on the retinas. 
 The possibility to see things is a process much more complex than the result of the 
light fall on the retina. Visual scenes are usually in a different way considered by different 
viewers. It depends on which aspect of the scene is being analyzed from the viewer, in other 
words where he is putting his attention. A very important factor by seeing is the knowledge 
and experiences the person had before. Many of the processes with influence on seeing and 
perceiving, take place without attention. Visual perception can be modulated through learning 
and knowing. 
 It is well established that response in neurons from the ventral stream are modulated 
by visual attention. Early studies identified the area V4 and the ventral stream as one of the 
main sites of attentional influences on visual processing. Recent studies have demonstrated 
similar influences in visual cortical areas within the dorsal stream. The source of these 
attentional modulatory influences likely arises from a network of frontal and parietal areas. 
 
5.3. Changes in Visual System in AD 
 There is clear evidence that AD involves a processing disorder that has his origins in 
the visual sensory pathway (Gilmore et al., 1994; Hof et al., 1990b; Hof and Morrison, 1990). 
The memory dysfunction is the hallmark of the AD Disease but before it appears there are 
other systems which already suffer from the neurodegeneration, like the visual system 
(Mendola et al., 1995). The sensory problems add to and exacerbate the memory problems. 
 Neuropathological alterations in AD precede cognitive impairment by several years. 
Functional changes occur before clinical symptoms appear and the visual system is very early 
involved in the pathological process. It is demonstrated in several studies with different tasks 
and different population groups. 
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 In the study of Cronin-Golomb et al. (Cronin-Golomb et al., 1991) visual deficits in 
the following functions were observed: color, stereoacuity and contrast sensitivity. They 
received a neuro-ophtalmological examination, and no abnormalities were found. These 
findings made the authors suggest that the widespread visual dysfunction reported were more 
likely to be related to known pathological changes in primary visual and association cortex in 
AD than to changes in the retina or optic nerve. 
 Sadun may have been the first to suggest that AD may involve a deficit in the 
magnocellular pathway neural system.(Sadun, 1989). It would mean that the magnocellular 
neurons of the dorsal pathway are more susceptible to degeneration than the parvocellular 
neurons of the ventral pathway. For some authors there is evidence for the fact that the 
magnocellular pathway is the part of the visual system more impaired (Gilmore et al., 1994; 
Mentis et al., 1996; Mentis et al., 1998). But there are other studies in which deficits in the 
magnocellular but also in the parvocellular pathway were shown (Cronin-Golomb et al., 
1991; Rizzo et al., 2000b; Rizzo et al., 2000a).  
 Mentis et al. (Mentis et al., 1996) demonstrated that the magnocellular visual system 
suffers a greater dysfunction than the parvocellular, so that the visuospatial evaluation of AD 
patients could be very useful for the characterization of the disease 
 In the investigation of individuals at risk for AD, like the study of Smith et al. (Smith 
et al., 1999), the authors demonstrate that cognitively normal individuals at a high risk for AD 
had a decreased brain activation in key areas engaged during naming and fluency tasks. They 
concluded that it may be a consequence of the presence of subclinical neuropathology in the 
inferotemporal region or in the inputs to that region. Thulborn et al. (Thulborn et al., 2000) in 
the same way studied a group of patients with probably AD and a control group using fMRI. 
The task was a visuospatial cognition task with an eye movement paradigm. The results 
obtained from the study, showed that a left dominant activation pattern and enhanced 
prefrontal cortical activation were observed in most of the patients in comparison with the 
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control group. So the reduction in right parietal activation producing the left-dominant pattern 
may reflect the progressive dysfunction in spatial attention associated with AD.  
 In conclusion, in the majority of the studies diminished intensity and/or extent of 
activation has been demonstrated in the frontal and temporal regions in patients with AD. 
Studies with “at-risk” populations showed mixed results with increased or decreased 
activation patterns. Some of the authors from all these studies explain their findings in terms 
of a compensatory-recruitment hypothesis, in which greater cognitive effort  is required from 
the patients to perform the same task (Petrella et al., 2003).    
 According to all these studies, fMRI has proved to be a powerful research technique 
for analyzing deficits in the very early stage of the pathological process of AD. When 
memory complains appear, the disease is already in an advanced stadium and some of the 
functional deficits (like in the visual system) appeared years before. 
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Figure 1. The primary Visual Cortex and the two Cortical Visual Systems 
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Anatomical connections of visual areas in the ventral and dorsal streams.  
The blue line indicates connexions between the early visual areas V1 and V2 to the middle temporal visual area MT. The red 
line indicates direct inputs from the peripheral field representations of V1 and V2, bypassing MT (they may provide rapid 
activation of regions mediating spatial attention). The green line indicates projections “intermediate-type” (they link areas 
between dorsal and ventral stream). 
MT-motion-sensitive area of the sup. temporal sulcus 
VIP-ventral intraparietal area 
TEO and TE- inferior temporal. They comprise together the inferior temporal (IT) cortex. 
(Adapted from Ungerleider, 1995 (Ungerleider, 1995)) 
 
 
„WHAT“
„WHERE“
17
19
18
19
7
45
21
37
46
 
Anatomical connections of Brodman areas in the ventral and dorsal streams. 
Shown are some of the greater regions of each stream (Brodman areas). Area 17 in the occipital lobe is the primary visual 
cortex. Area 18 and 19 are located in the occipital cortex as well. In the ventral pathway area 37 and 21 are located in the 
inferior temporal cortex and area 45 is located in the frontal cortex. 
In the dorsal pathway the area 7 is located in the parietal cortex and area 46 is located in the prefrontal cortex. 
Take note that nomenclature of Brodman areas is still approximate. 
(Adapted from B.J.Krause and H.-W. Müller-Gärtner (Krause and Müller-Gärtner, 2005)) 
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6. OBJECTIVE OF THE WORK 
 
 Accurate visual function facilitates memory, attention and executive functions, so that 
perceptual dysfunction contributes to the severity of cognitive impairment (Rizzo et al., 
2000b). Visual system deficits due to the Alzheimer’s pathology have already been 
investigated and it is shown that AD involves disorders in the visual sensory pathways. 
 The objective of the work is to measure changes in activation in the visual system 
between MCI patients and old HC subjects using fMRI. This is the first study which makes 
such a comparison between MCI and old HC using fMRI.   
 For the study, two different visual processing tasks have been designed in a manner 
that they activate selectively the ventral and dorsal pathway in healthy people. This work 
seeks to identify abnormalities in visual system in MCI subjects due to the pathological 
changes in brain before behavioral performance is impaired, thereby providing the possibility 
of an earlier diagnosis of AD. 
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7. SUBJECTS AND METHODS 
7.1. The patient group 
7.1.1. Inclusion and Exclusion Criteria 
Inclusion Criteria   
 -Age less than 80 years 
 -MMST over 20 
 -Diagnosis of MCI with amnestic component (Petersen et al., 1999): the patient must 
be neither normal nor demented (does not meet criteria (DSM IV, ICD 10) for a Dementia 
syndrome). There must be a marked cognitive decline (reported by the patient and/or 
informant) and impairment in objective cognitive tasks and/or evidence of decline over time 
in objective cognitive tasks. Basic activities of daily living must be preserved and minimal 
impairment in complex instrumental functions is necessary for the diagnosis.  
Exclusion Criteria  
 -Brain vascular damage (as a risk of Vascular Dementia) 
 -Arterial hypertension (as defined by consistent blood pressure values over 160/95) 
 -Diabetes mellitus (as defined by fasting glucose levels over 140 mg/dl with or 
without therapy) 
 -Depression (as defined by Hamilton Depression Rating Scale over 12) 
 -Any other neurological or psychiatric pathology 
 -Metal implants and/or pacemaker.  
 
7.1.2. Description of the Group 
 Sixteen patients were included in the study. All patients received an explanation of the 
study and gave their written consent. The study was approved by the Ethics Committee of the 
Medical Faculty of Ludwig Maximilian University. The Group was composed of 8 women 
with an average age (standard deviation) of 68.38 (8.535) and 8 men with an average age 
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(standard deviation) of 71.50 (7.25). 
 The average (standard deviation) of the MMST was 27.88 (1.63) for the whole group.  
Age and gender distribution was matched between groups. There were statistically significant 
differences between healthy control and MCI group in the MMST Score at the p<0.05 level.
  
 
7.2. The old healthy people group 
7.2.1. Inclusion and Exclusion Criteria 
Inclusion Criteria   
 -Age less than 80 years 
 -MMST over 20 
 -Healthy people status is determined by different means to reject medical, 
neurological, psychiatric and Dementia illness: history, physical and neurological 
examinations, mental status examination and neuropsychological evaluation. 
Exclusion Criteria  
 The exclusion criteria for the old healthy group were the same as for the patient group. 
 
7.2.2. Description of the Group 
 There were 19 old healthy people (OH) included in the study. All of them gave written 
consent to participate as well. The group was composed of 11 women with an average age 
(standard deviation) of 68.18 (5.29) and 8 men with an average age (standard deviation) of 
66.00 (3.46).  The average (standard deviation) of the MMST was 29.16 (1.015) for the whole 
group. 
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7.3. Physical and Neuropsychological Examination 
a) History 
 To investigate predisposing factors, personal and family medical histories were 
required. The subjects received particular attention when the history suggested the presence of 
cardiovascular disease, hypertension, diabetes, inflammatory disease, or Dementia in the 
family history. 
 
b) Physical and neurological examinations 
 Vital signs were examined to determine the presence of systemic or neurological 
abnormalities. 
 Elemental neurological examination: cranial nerve abnormalities (including visual 
fields), motor (voluntary and extrapyramidal), sensory signs, impairments of gait or 
coordination and abnormal and asymmetric reflexes. 
 
c) Mental status examination 
 The mental status examination is a systematic assessment of an individual’s quality of 
mental functioning.  It is the primary clinical tool for examining and understanding cognition, 
emotion and behaviour.  Because of some patients demonstrating abnormalities of mental 
function without clear abnormalities in general physical or neurological condition, mental 
status examination is one part of a more comprehensive clinical examination. 
 The essential elements of the mental status examination are:  
-General: appearance and behaviour, speech, thought process and content, emotion 
-Cognitive: arousal, attention, language, memory, recognition 
 
d) Laboratory examination 
 -Electroencephalography (EEG): slowing on the EEG tends to increase in proportion 
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to the degree of cognitive impairment. It can be useful for the differential diagnosis between 
Delirium and Dementia. 
 -Battery of standard Tests to identify a suspected underlying etiology: complete blood 
count, serum chemistries (creatinine and blood urea nitrogen, liver function tests), vitamin 
B12, folate, thyroid stimulating hormone (TSH), and serum syphilis serology. 
 -Structural Neuroimaging study: Magnetic Resonance Imaging (MRI) can provide 
definitive information on the cause of a Dementia 
 -Lumbar puncture 
 
e) Neuropsychological evaluation tests 
 It is necessary when additional information on the pattern and extent of cognitive 
impairments is needed to clarify the diagnosis and to guide treatment planning. 
 -MMSE: This is a test which lasts about 10 min, it is used to evaluate grade of 
Dementia (Folstein et al., 1975).  It includes merely cognitive aspects but not mood state or 
psychotic symptoms. The scores vary between 0 and 30 points, where 0-11 points represents 
severe Dementia, 12-18 middle-severe Dementia, 19-23 mild Dementia, 24-26 cognitive 
impairment, and 27-30 unimpaired efficiency. The test includes orientation, attention, 
memory and language exercises from daily living  
 -CERAD (Consortium to Establish a Registry for Alzheimer’s disease): a battery of 
clinical and neuropsychological tests for patients with Alzheimer’s disease which lasts about 
40 min. These tests measure the primary cognitive manifestations of AD across a range of 
severity, and discriminate between normal subjects and those with mild and severe Dementia 
(Morris et al., 1989a). It is composed of seven tests: 
1) Verbal fluency 
2) Boston Naming Test: 15 words from one category must be given 
3) MMSE 
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4) 10 words have to be memorized in three passages 
5) Constructive praxis 
6) Unprompted recall of the memorised 10 words 
7) Identification of the memorized words from a larger list of words. 
 
This battery is scored by the individual test. There is no cumulative score.  
For detailed patient characteristic see tables 3 and 4. 
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Table 3.  CERAD scores for the OHC group 
 
Controls sex MMSE Word  
List 1 
Word  
List 2 
Word  
List 3 
Word 
 List 1-3 
1 man 30 7 8 10 25 
2 Man 28 7 8 8 23 
3 woman 29 6 10 10 26 
4 man 30 8 9 10 27 
5 man 29 4 7 8 19 
6 woman 30 8 10 10 28 
7 man 29 6 9 9 24 
8 woman 29 9 9 10 28 
9 man 30 7 8 10 25 
10 woman 26 5 8 10 23 
11 woman 28 7 8 10 25 
12 man 30 6 7 8 21 
13 woman 30 5 7 6 18 
14 man 30 8 9 10 27 
15 woman 30 7 8 9 24 
16 woman 29 6 7 9 22 
17 woman 29 4 7 8 19 
18 woman 30 7 8 10 25 
19 woman 29 7 8 10 25 
 
 
Table 3.  continued 
 
 
Controls sex Word 
 Recall 
Word 
Recognition 
Word 
Flow 
Name Drawing 
1 man 10 10 23 15 11 
2 Man 8 9 25 13 11 
3 woman 10 10 37 14 10 
4 man 10 10 36 15 11 
5 man 6 10 13 13 11 
6 woman 10 10 24 15 10 
7 man 6 10 21 15 10 
8 woman 10 10 29 15 8 
9 man 8 10 19 15 11 
10 woman 9 10 20 15 11 
11 woman 9 10 30 15 11 
12 man 8 10 21 15 11 
13 woman 6 10 24 14 10 
14 man 10 10 22 15 11 
15 woman 8 10 15 14 11 
16 woman 7 10 13 15 9 
17 woman 4 10 23 14 10 
18 woman 9 10 30 15 11 
19 woman 9 10 33 15 11 
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Table 4. CERAD scores for the MCI group 
 
Controls Sex MMSE Word 
List 1 
Word 
List 2 
Word 
List 3 
Word 
List 1-3 
1 woman 29 4 7 7 18 
2 woman 26 4 5 5 14 
3 woman 25 2 3 4 9 
4 man 27 5 6 6 17 
5 man 28 4 3 7 14 
6 man 29 4 5 7 16 
7 man 25 4 5 6 15 
8 woman 24 4 5 6 15 
9 woman 28 7 8 6 21 
10 man 27 3 6 7 16 
11 woman 27    18 
12 man 28 2 3 4 9 
13 woman 27 4 8 9 21 
14 woman 29    19 
15 man 28 4 4 6 14 
16 man 28 4 6 8 18 
 
 
Table 4. continued 
 
 
Controls Sex Word 
Recall 
Word 
Recognition 
Word 
Flow 
Name Drawing 
1 woman 2 7 15 15 11 
2 woman 2 10 17 13 11 
3 woman 0 4 12 14 10 
4 man 5 8 17 15 11 
5 man 5 9 17 13 11 
6 man 5 7 17 15 10 
7 man 4 9 12 15 10 
8 woman 4 7 9 15 8 
9 woman 4 8 18 15 11 
1 man 4 9 18 15 11 
1 woman 0 8 18 15 11 
12 man 2 10 26 15 11 
13 woman 5 10 16 14 10 
14 woman 7 9 25 15 11 
15 man 5 10 15 14 11 
16 man 6 10 15 15 9 
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7.4. Stimuli and Tasks 
 Two different tasks were used: face matching (for form discrimination) and location 
matching (for spatial location). In each the subjects gave their responses by pressing a button. 
 
Face matching + Perception: 
 Two types of stimulus displays were used.  
 In the first task (Perception), a series of pairs of identical abstract images appear and 
disappear continually. The subjects were asked to press the button every time the pictures 
appeared. This task was used as a control task. 
 In the second task (face matching), the subjects were shown pairs of faces. The 
subjects were asked to identify the pair of faces that were identical by pressing the button. 
Unmatched pairs required no response (see Figure 2). The faces were grey scale stimuli and 
they were from the Max Planck Institute for Biological Cybernetics database.  
 
Location matching + Perception: 
 Two types of stimulus displays were used. 
 The first task was also a control, the same as the previously described perception task. 
In the second task, pairs of identical abstract images were shown positioned inside larger 
squares (see Figure 3). The subjects were asked to identify those pairs in which the images are 
in the same position relative to the larger squares. These were identified by pressing the 
button. Pairs with mismatched positions required no response. 
 
 The presentation of each trial lasted 2.8 sec, and the intervals between them were 
0.318 sec. All stimuli were presented in grey scale. There were 8 trials per block and there 
were 3 blocks in each scan. 
 Because the instructions for each trial were shown at the beginning of each block, 
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appearing for 7.2 sec., the subjects always knew which trial came as next.  The different 
conditions were counter-balanced across subjects. 
 In the control task there were 4 blocks with the same length as the task of interest. The 
parameters of presentation of the images were identical to the task of interest. 
 Performance was monitored during the task, counting correct answers and reaction 
time. 
 The test was a block design, beginning with a red cross as a fixation point (4 volumes). 
Control task and the Task of interest (7 volumes each) alternated. Every part was preceded by 
an instruction (2 volumes).  
 
Checkerboard 
 A visual sensory paradigm was developed to assess differences in response of the 
blood oxygenation level dependent (BOLD) signal to a visual stimulus between the two 
groups. It was compound by a red cross as a fixation point and a flashing checkerboard. 
The third task was a passive sensory stimulation paradigm, block design, with alternating 
blocks of fixation or a flashing checkerboard at 8 Hz. The blocks were 20 seconds long with 
the three blocks of stimulus and 4 blocks of fixation. The sensory task was performed in the 
same session as the object and location matching task.  
 The subjects were asked just to look at both visual stimuli. They did not need to give 
any response. 
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Figure 2.  Face Matching Task 
 
 
 
 
 
 
 
 
 
 
 
   Trial with identical faces 
 
 
 
 
 
 
 
 
 
 
   Trial with different faces 
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Figure 3. Location Matching Task 
 
 
 
 
 
 
 
 
 
 
 
   Trial with the same position 
 
 
 
 
 
 
 
 
 
 
   Trial with different positions 
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7.5. MRI scanning 
 The goal of fMRI is to map physiological changes in the brain over time related to an 
experimental stimuli presentation. Looking at a single image does not provide information 
about brain activity. We need to examine changes over time to isolate the effects caused by 
the stimuli. 
 The data are collected in time series, a large number of images of the brain collected in 
temporal order, so that they can be correlated to stimuli presentation. Each experimental 
session includes the collection of anatomical images and a number of runs of functional 
images. Every run lasts for 5 to 10 min. and includes the sequence of the stimuli presentation. 
It is necessary to break the stimuli presentation into short runs because otherwise the subjects 
would become very quickly tired. The acquisition of the data within each run occurs as a time 
series of volumes. Every volume includes all number of slices what we measure in our TR 
(repetition time). One volume can include the whole brain or a part of it (if we are interested 
in one specific region, we do not need to get data from the whole brain). Every volume is 
composed of a number of slices of the brain and the whole number of slices, which are 
included in one volume, are collected during the TR. Every slice image is taken at a different 
time point within the TR, but the information within a slice corresponds to the same time 
point. Each slice contains thousands of voxels (2n ×2n matrix of voxels). All voxels from all 
slices together compose the image of the brain. When we acquire our data, we can think about 
our data like a four dimensional matrix (x, y, z, time).  
 When we examine changes in voxel activation, it may reveal if the increase or 
decrease of their activation is correlated to the presentation of the stimulus. Functional MRI 
analysis attempts to detect the small changes in MR signal associated with the BOLD effect, 
but to ignore the effect of noise. 
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7.5.1. Data acquisition 
 The subjects were scanned on a 1.5 Tesla Siemens Magnetom Vision Scanner 
(Erlangen, Germany) (see Figure 4).  
 Vacuum mattresses and bandages around the forehead were used to reduce head 
movements. The subjects were asked to try do not move at all. 
 The stimuli were projected on a screen located in front of the scanner at about five 
meters away from a mirror mounted on the head coil. The visual stimuli projected on the 
screen were reflected on the mirror, so that the subjects were able to see them while lying in 
the scanner. The answers were giving pressing a button (see Figure 4). 
 The imaging sequence was an intervaled T2* weighted echo planar sequence with 28 
axial slices (4 mm slice thickness and slice gap = 1mm, repetition time (TR) = 60 ms, echo 
time (TE) = 60 ms, flip angle = 90°, filed of view = 240 mm. Matrix 64 × 64) and 69 frames 
acquired per scan. For anatomical reference in each subject, a T1 weighted sequence with 28 
slices was acquired in the same orientation as the EPI (echo planar imaging) sequence (TR = 
620 ms, TE = 12 ms, flip angle = 90°, FOV = 270 mm, matrix = 224 × 256, Rect. FOV = 7/8, 
Effective Thickness = 1.25 mm).  
 
7.6. Analysis of fMRI data 
7.6.1. Analysis tools  
Preprocessing of fMRI Data: 
fMRI data contains not only brain activation information, but may also contain 
information due to subject head motion, physiological factors like heart beats and respiration, 
lack of homogeneities in the magnetic static field and differences in the image acquisition.  To 
have a high detection power in our experiment, we need to correct for all these factors. 
 Preprocessing of the fMRI data consist of following image reconstruction and it 
prepares our data before statistical analysis. All the factors not due to the experiment are 
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removed and signal-to-noise-ratio (SNR) is increased. 
a) Slice acquisition Time Correction: the data acquisition occurs usually in a two 
dimensional pulse sequence, so that one slice will be acquired at a time. A typical pulse 
sequence acquires 24 slices covering the whole brain within a TR of 1.5 to 3.0 sec. 
(depending on the capability of the scanner). The acquisition of the slices may be sequential 
or interwoven. For the interwoven acquisition, the most common one, the odd slices are 
acquired first, and then the even slices to avoid cross-slice excitation. Every slice is collected 
at a different time point.  We use temporal interpolation to correct this effect. The information 
of the nearby time points is used to estimate the value of the signal at a time point that was not 
originally collected. Some different techniques can be used: linear, spline and sinc functions; 
but none of them can recover the whole information lost. There are two factors which 
influence the accuracy of interpolation: the variability in the experimental data and the TR. 
b) Head motion correction: the most common problem for fMRI studies are head 
movements. The basic problem with head motion is that in the analysis process of fMRI data 
every voxel is considered as a unique part of the brain. If the subject moves his head about 5 
mm, the information related to one voxel will be derived from two parts of the brain which 
are separated 5 mm of each other. Head motion is more easily prevented than corrected for, so 
the use of head restraints avoids much of the possible movement. 
If some head movements occur during the experiment, the activation will be located in 
the wrong place. Motion correction is used to align the brain in every time series so that the 
position is staying constant. The process to align two image volumes in the time series is 
called coregistration. The goal of having the brain in the same position at all times can be 
achieved by the coregistration of successive volume images to a single reference volume. We 
use a rigid body transformation which assumes that the size and shape of two objects to be 
coregistrated are identical and that the one can be superposed to the other by the combination 
of three translations and three rotations. 
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To determine the amount of head movement, the translation and rotations during the 
experiment are computed, it allows matching the data with the reference volume. For that, we 
do a spatial interpolation which considers points in two or three dimensions. We have three 
methods which fit our desired results: linear interpolation, sinc interpolation and spline 
interpolation. 
c) Distortion correction 
Functional images often suffer from intensity and geometric distortions. They are due 
to the magnetic field inhomogeneities. One approach to correct this distortion is called 
magnetic field mapping. It provides information about the static magnetic field, so that we can 
correct our data. 
d) Functional-Structural Coregistration and Normalization 
The objective is an optimal match between the functional data and the anatomical data. 
To reach this goal we need: 
-functional-structural coregistration: computational processes to match functional and 
structural images. It is needed for example because of image distortion, because some pulse 
sequences used to acquire functional images may introduce subtle geometric distortions. 
  -spatial normalization: every brain is unique in his structure, so when we want to 
make comparisons between subjects we need to have the anatomical structures located in the 
same place. The goal of normalization is to compensate for  differences by stretching, and 
warping the images of the brain. In this way, it is possible for us to find the three-dimensional 
coordinates in a stereotaxic space. There are two standard brain structure templates we use. 
The most common one is the Talaraich space, which was created from one single brain. The 
other is the Montreal Neurological Institute template (MNI), which consists of an average 
152-T1 weighted brain images. 
e) Spatial and Temporal Filtering 
In neuroimaging filters are used to remove uninteresting variation in the data that can 
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be attributed to noise, and to preserve signals of interest, so that filtering can be used to 
increase functional Signal-Noise Ratio (SNR). 
By  temporal filtering we try to keep changes which occur at the task frequency and to 
reduce changes in the data which occurs at other frequencies. It depends on our test, the 
facility to remove selective noise components, such as those introduced by the physiological 
processes. If we have a slow stimuli presentation frequency, it should be easy to separate this 
frequencies from those due to physiological process, like respiration. But if we have for 
example a fast event-related design it can be more difficult. 
Spatial filtering can increase the functional SNR, at a cost of reduced spatial 
resolution. SNR varies across space because the signal is greater in these voxels associated 
with the task than in voxels with little to no no task-related activity. Noise varies over space, 
as well. 
 
Statistical analysis of the Data 
fMRI studies try to find a weak signal in the presence of substantial noise, so careful 
statistical analysis are necessary.  
The goal of the fMRI statistical analysis method is to determine if every voxel is 
consistent with the null hypotheses. Experiments are designed to discriminate between two 
possible hypotheses: the research hypothesis (H1) and the null hypothesis (H0). When the 
statistical results from all voxels in the brain are combined, we obtain a statistical map of 
brain activity, which is colour-coded according to the probability value for each voxel. The 
association between the probability values and the colours that label them, is known as color 
map. 
We use the General Linear Model to treat our data. We assume with this model that 
the experimental data are a linear combination of a number of factors plus noise.  The 
equation for a univariate multiple regression model, which represents fMRI data is: 
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y = a0 + a1x1 + a2x2 + ……+ anxn + ε 
where ai  are the parameter weights, xi are the model factors, ε is the additive error and y are 
the observed data. We can extend it to have a large number of dependent variables so that we 
reach the general linear model.  
In the general linear model we create a design matrix (n time points × M model 
factors) with the factors of interest and the other factors, which introduce variability in the 
data but are not relevant to our results (nuisance factors). We construct the design matrix 
based on the study design and explain in it how the model factors change over time. In our 
model we also have the parameter matrix (M model factors × V voxels) and the error 
matrix (n time points × V voxels), which are calculated in the analysis. The empirical data 
(fMRI data) are obtained experimentally (see Table 5). 
 
7.6.2. Analysis process 
 The Data was analyzed on a computer with an Intel Pentium CPU (San Jose, 
California, USA) running LINUX (Red Hat version 7.0, Red Hat Inc Rayleigh, North 
Carolina, USA) using AFNI (Cox, 1996) (available at  afni.nimh.nih.gov/afni/) and FSL 
(FMRIB Software Library-available at www.fmrib.ox.ac.uk/fsl) as analysing software. 
 The first step was to delete the first 4 volumes of each scan corresponding to the 
fixation point (Red Cross). The remaining data was corrected for the timing differences 
between each slice using Fourier interpolation. After that the data was corrected for motion 
effects (6-parameter rigid body), where the reference volume was in the middle of the run. 
 Using FSL, every run was analyzed using a fixed effects general linear model. Each 
model was composed of the following regressors: the one indicating the task of interest, one 
for the instructions (the time derivates of the two previous regressors), and regressors for 
motion during the run. The task and instructions were square waveform models (on-off). The 
regressors for the task of interest and instructions were convolved with a standard double 
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gamma hemodynamic response function. The data were smoothed (Gaussian filter at full 
width at half maximum = 8×8×8 mm ) and high pass filter with a cutoff at (1/100) Hz. The 
normalization was made according to the Montreal Neurological Institute/International 
Consortium for Brain Mapping 152 standard (MNI/ICBM). The location of activation areas in 
the brain was done in reference to the Talaraich and Tournoux template (Talaraich and 
Tournoux, 1988). To transform coordinates from one template to another, a non-linear 
transformation developed by M. Brett was used (http//:www.mrc-
cbu.cam.ac.uk/Imaging/mnispace.html). 
 The group statistical analysis was based on a random effects model with a statistical 
threshold of Z = 2.33 (p< 0.01) and each cluster was corrected for multiple comparisons at the 
p<0.05 level.  
 The structural images of the non-brain tissue were edited out using BET and manually 
edited for any remaining non-brain tissue on the images. The EPI images were first co-
registered to the 28-slice T1 weighted image (7-parameter rigid body), the 28-slice T1 
weighted image was registered to the MPRAGE image, and the MPRAGE image was 
registered to the MNI/ICBM template (12 parameter). The statistical results from each subject 
were transformed into the MNI/ICBM stereotaxic space for group analysis. 
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Table 5. Basic principles of the general linear model  
X (n,V) = +     ε×G
(n,M)
β(M,V)
Total variability Variability explained by the model Noise
 
Basic principles of the general linear model.  
X represents the fMRI data, G is the design matrix, ß is the parameter matrix and ε the error matrix. 
Adapted from Huettel at al. (Huettel et al., 2004) 
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Figure 4 .fMRI buttons and scanner                  
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8. RESULTS 
 The description of the brain activation patterns for both tests (object and location 
matching) in the old healthy control group and in the patient group are explained in this 
chapter. The differences in brain activation patterns between tasks and between groups were 
analyzed as well. 
 The tables of activation peaks include the highest 10 statistically significant peaks (as 
a function of the Z value). 
 In addition, behavioural performance (percent of correct answers and mean response 
time) was also recorded, and it is described in this chapter. 
 
8.1. Behavioural Performance 
 The mean value (standard deviation) in performance of the MCI group in face 
matching was 87.76 (11.33) and for location matching 91.14 (8.85), showing that the patients 
were able to resolve the exercises and were paying attention during the task (see Table 6). The 
mean value (standard deviation) for the response time during the face matching task was 1.46 
(0.32) and for the location matching task was 1.55 (0.40). 
 In the HC group the performance results in the face matching task were 91.67 (7.21) 
and for location matching 92.98 (10.21). 
 The mean response time was 1.53 (0.32) for face matching and 1.36 (0.36) for location 
matching (see Table 7). 
 Performance in face matching and location matching were not significantly different 
between the groups. There is no statistically significant difference between the two tasks 
within each group. 
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8.2. Task activation in the Healthy Control Group 
a) Object Matching 
 The highest 10 statistically significant activation peaks shown in Table 8 and Figure 5 
are the results of the contrast made between the brain images recorded during the object 
matching task compared to those of the control task. 
The healthy control group showed brain activation in the following areas of the right 
hemisphere: Fusiform Gyrus and Precuneus (Occipital Lobe), Inferior Parietal Lobe, Inferior 
and Middle Frontal Gyrus, and Anterior Cingulate Gyrus (Frontal Lobe).  In left hemisphere 
the activated areas were located: in the Inferior Occipital Gyrus and Fusiform Gyrus 
(Occipital Lobe), as well as in the Inferior Frontal Gyrus. 
 
b) Location Matching 
 The network recruited during location matching compared to the control condition for 
the group is shown in Table 9 and Figure 7. In the right hemisphere activation was found in 
the Middle Occipital Gyrus and Precuneus (Occipital Lobe), in the Inferior Parietal Lobulus 
(Parietal Lobe), and in the Inferior Frontal Gyrus (Frontal Lobe).  In the left hemisphere the 
activation peaks were found in the Inferior and Middle Occipital Gyrus, and Precuneus 
(Occipital Lobe), in the Inferior Parietal Lobulus (Parietal Lobe).   
 
8.3. Task activation in the Mild Cognitive Impaired group 
a) Face Matching 
 The highest statistically significant activation peaks shown in Table 10 and Figure 6 
are the results of the contrast made between the brain images recorded during the object 
matching task compared to those of the control task 
   In the right hemisphere: in the Inferior Occipital Lobe and Fusifom Gyrus (Occipital 
Lobe), in the Inferior Temporal Gyrus, Inferior Parietal Lobulus, in the Inferior and Middle 
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Frontal Gyrus (Frontal Lobe). In the left hemisphere, the activation in the Occipital Lobe took 
place in the Inferior and Middle Occipital Lobe, and in the Frontal Lobe in the Inferior 
Frontal Gyrus.  
b) Location Matching 
 In the contrast between location matching compared to the control condition for the 
group, there were some activation peaks, which are shown in Table 11 and Figure 8. In the 
right hemisphere we found activation peaks in Precuneus, Middle Occipital Gyrus and 
Occipital Gyrus (Occipital Lobe), in the Superior Parietal Lobulus, and in the Inferior Frontal 
Gyrus. In the left hemisphere the activation in the Occipital Lobe took place in the Precuneus 
and Occipital Gyrus, in the Temporal Lobe in the Hippocampal Gyrus, in the Parietal Lobe in 
the Superior Parietal Lobulus, in the Frontal Lobe the activation peaks were found in the 
Inferior, Middle and Frontal Gyrus. 
 
8.4. Differences in activation between task within groups  
8.4.1. Healthy Control Group 
a) Face matching versus location matching 
 The differences in activation peaks in the HC group by the contrast face matching 
versus location matching are listed in the Table 12. In the right hemisphere the activation 
peaks found were located: in Cuneus, Lingual Gyrus, Inferior Occipital Gyrus and Fusiform 
Gyrus (Occipital Lobe), in the Inferior and Superior Temporal Gyrus (Temporal Lobe), in the 
Medial, Inferior and Superior Frontal Gyrus, as well as the Anterior Cingulate Gyrus (Frontal 
Lobe). The Basal Ganglia also had an activation peak in the Thalamus. 
 In the left hemisphere the activation peaks were found: in the Lingual Gyrus (Occipital 
Gyrus), in the Parahippocampal Gyrus (Temporal Lobe), and in the Inferior, Middle and 
Superior Frontal Gyrus, as well as in the Anterior Cingulate Gyrus (Frontal Gyrus).    
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b) Location matching versus face matching 
 The activation peaks in the HC group for the contrast location matching versus face 
matching are shown in the Table 13. The activation in the right hemisphere was located in the 
Occipital Gyrus. In the Parietal Lobe the activation was bilateral. 
 
8.4.2. Mild Cognitive Impaired Group 
 Within the MCI group, there were no regions that were more activated in the face 
matching task compared to the location matching task and vice versa. 
 
8.5. Differences in activation between groups 
a) Face matching 
 In the face matching task there were no differences in activation in the contrast 
between groups compared to the other group.  
b) Location matching 
 In the location matching task the contrast of higher activation of HC compared to MCI 
showed no statistically significant differences. 
 The activation peaks in Table 15 and Figure 10 shows the differences in the contrast of 
higher activation in MCI compared to HC. The activation peaks were found in the Medial 
Frontal Gyrus bilateral. In the left hemisphere activation peaks were found in the Inferior, 
Middle and Superior Frontal Gyrus.   
 
8.6. Passive Sensory Task 
 Both groups activated the primary visual areas of the brain during the passive 
stimulation paradigm. The contrast comparing differences in activation between both groups 
showed no statistically significant differences. 
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Table 6 . Behavioural Performance of the MCI group 
 
  N Minimum Maximum Mean 
Standard 
deviation 
Face Performance 16 58,33 100,00 87,7577 11,33011 
Face Response Time 16 1,0407 2,1990 1,458744 ,3179030 
Location Performance 16 66,67 100,00 91,1438 8,85287 
Location Response Time 16 ,9812 2,1558 1,547031 ,3951710 
 
 
16         
 
Performance is given in % correct answers. 
The response time units are seconds. 
 
 
Table 7. Behavioural Performance of the HC Group 
 
  N Minimum Maximum Mean 
Standard 
deviation 
Face Performance 19 75,00 100,00 91,6667 7,21560 
Face Response Time 19 ,9658 2,2414 1,530695 ,3227906 
Location Performance                           19 62,50 100,00 92,9795 10,21287 
Location Response Time 19 ,8022 2,0735 1,364053 ,3649103 
 19         
 
Performance is given in % correct answers. 
The response time units are seconds. 
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Table 8.  Main Activation Peaks during Object Matching Task in Healthy Controls 
 
 
RIGHT HEMISPHERE 
 
Region    Brodmann Area x y z Z value 
Occipital Lobe 
Fusiform Gyrus    19  36 -71     -12 5.37 
Precuneus     19  28 -60 40 5.27 
 
Parietal Lobe 
Inferior Parietal Lobulus   40  38 -43 41 5.16 
 
Frontal Lobe 
Inferior Frontal Gyrus   44  44 15 23 5.94 
 
Middle Frontal Gyrus    46  48 23 25 5.96 
 
Anterior Cingulate Gyrus   32  8 21 32 5.36 
 
LEFT HEMISPHERE 
 
Region    Brodmann Area x y z Zvalue 
Occipital Lobe 
Inferior Occipital Gyrus   18  -30 -92 -6 4.57 
      18  -48 -86 -9 4.81 
 
Fusiform Gyrus    37  -46 -51 -18 5.02 
 
Frontal Lobe 
Inferior Frontal Gyrus   44  -44 5 31 4.67 
 
 
 
The location of the activation peaks are located with reference to the Talaraich und Tourneaux stereotaxic template. The 
coordinates  x+ are located in the right hemisphere. The coordinates y+ are located anterior to the anterior comisure, and the 
coordinates z+ are located superior to the AC-PC plane. 
The distances are given in mm. 
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Table 9.  Main Activation Peaks During Location Matching in Healthy Controls. 
 
RIGHT HEMISPHERE 
 
Region    Brodmann Area x y z Zvalue 
Occipital Lobe 
Middle Occipital Gyrus   19  32 -81 10 4.98 
Precuneus     7  14 -70 35 4.95 
      7  16 -60 52 4.73 
 
Parietal Lobe 
Inferior Parietal Lobulus   40  28 -58 42 5.25 
 
Frontal Lobe 
Inferior Frontal Gyrus   44  42 11 30 4.50 
 
LEFT HEMISPHERE 
 
Region    Brodmann Area x y z Zvalue 
 
Occipital Lobe 
Inferior Occipital Gyrus                                 18                  -36      -84        -9          4.39 
Middle Occipital Gyrus                                  19                  -32      -81       15           5.34 
Precuneus                                                          7                  -12     -62        47           4.73 
                                                                        18                  -18     -70        29           5.36 
 
Parietal Lobe 
Inferior Parietal Lobulus                                  40                 -38      -39       31           4.47 
 
 
The location of the activation peaks are located with reference to the Talaraich und Tourneaux stereotaxic template. The 
coordinates  x+ are located in the right hemisphere. The coordinates y+ are located anterior to the anterior comisure, and the 
coordinates z+ are located superior to the AC-PC plane. 
The distances are given in mm. 
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Table 10.  Main Activation Peaks During Object Matching in Mild Cognitive Impaired 
Subjects. 
 
RIGHT HEMISPHERE 
 
Region    Brodmann Area x y z Zvalue 
Occipital Lobe 
Inferior Occipital Lobe                              19                        34     -92       12             4.82 
 
Fusiform Gyrus                                          18                        40     -75      -13            5.09 
 
Temporal Lobe 
Inferior Temporal Gyrus                           19                         50     -74       -1             4.54 
 
Parietal Lobe 
Inferior Parietal Lobulus                           40                         40     -54      56             4.78 
 
Frontal Lobe 
Inferior Frontal Gyrus                               45                         38      30        8              4.81 
 
Middle Frontal Gyrus                                 9                         48      11        34             4.75 
 
 
LEFT HEMISPHERE 
 
Region    Brodmann Area x y z Zvalue 
 
Occipital Lobe 
Inferior Occipital Lobe                             18                        -36     -92       -6              4.97 
 
Middle Occipital Lobe                              19                        -46    -76        -5              4.68 
 
Fusiform Gyrus                                         19                        -50    -70       -12             4.86 
  
Frontal Lobe 
Inferior Frontal Gyrus         44               -46    15 25      4.88 
 
 
The location of the activation peaks are located with reference to the Talaraich und Tourneaux stereotaxic template. The 
coordinates  x+ are located in the right hemisphere. The coordinates y+ are located anterior to the anterior comisure, and the 
coordinates z+ are located superior to the AC-PC plane. 
The distances are given in mm. 
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Table 11.  Main Activation Peaks During Location Matching in Mild Cognitive 
Impaired Subjects. 
 
RIGHT HEMISPHERE 
 
Region    Brodmann Area x y z Zvalue 
Occipital Lobe 
Fusiform Gyrus                                        37                        54       -59      -14            4.21 
 
Middle Occipital Gyrus                           19                        44       -85        15            4.59 
 
Occipital Gyrus                                        19                        34       -76        30            4.36 
Parietal Lobe 
Superior Parietal Lobulus   7  32 -54 54    4.38 
 
Frontal Lobe 
Inferior Frontal Gyrus                                  46                     46         38       11           4.28 
 
 
LEFT HEMISPHERE 
 
Region    Brodmann Area x y z Zvalue 
Occipital Lobe 
Precuneus                                                       7                     -18      -77      48          4.41 
     
Occipital Gyrus    19  -32 -84 28   4.35 
 
Temporal Lobe 
Hippocampal Gyrus                                       36                    -18      -22     -21         4.85 
 
Parietal Lobe 
Superior Parietal Lobulus                                7                     -32     -59      58          4.08 
Frontal Lobe 
Inferior Frontal Gyrus                                    47                     -50      27       -1         3.49 
Middle Frontal Gyrus                                      9                     -54      18      -15         3.81 
Superior Frontal Gyrus                                    6                     -32       7        59         3.45 
 
 
The location of the activation peaks are located with reference to the Talaraich und Tourneaux stereotaxic template. The 
coordinates  x+ are located in the right hemisphere. The coordinates y+ are located anterior to the anterior comisure, and the 
coordinates z+ are located superior to the AC-PC plane. 
The distances are given in mm. 
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Table 12.  Location of Statistically Significant Higher Activation Peaks During Face 
Matching Compared to Location Matching Task in Healthy Control Subjects. 
 
 
RIGHT HEMISPHERE 
 
Region    Brodmann Area x y z Zvalue 
Occipital Lobe 
Cuneus     17  20 -75  8 2.97 
      31  14 -64  7 3.76 
 
Lingual Gyrus     19  16 -58 -4 3.19 
      18  22 -101 -5 4.15 
        36 -70 -7 4.65 
 
Inferior Occipital Gyrus   18  38 -82 -4 4.26 
 
Fusiform Gyrus    37  40 -49 -16 5.52 
 
Temporal Lobe 
Inferior Temporal Gyrus   20  30 -6 -38 4.21 
        32 -8 -33 3.97 
        31 -5 -27 3.62 
        44 2 -37 3.39 
 
Superior Temporal Gyrus   38  22 9 -24 3.53 
 
Frontal Lobe 
Medial Frontal Gyrus    8  0 28 52 2.80 
      9  8 42 24 2.94 
 
Anterior Cingulate Gyrus   32  6 23 34 3.30 
 
Inferior Frontal Gyrus   47  37 19       -13 3.56 
 
Superior Frontal Gyrus   9  10 58 34 3.19 
        10 60 28 3.29 
Basal Ganglia 
Thalamus       6 -17   3 3.19 
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Table 12. continued 
 
 
LEFT HEMISPHERE 
 
Region    Brodmann Area x y z Zvalue 
Occipital Lobe 
Lingual Gyrus     19  -12 -57 -6 4.71 
 
Temporal Lobe 
Parahippocampal Gyrus   28  -16 -10 -13 3.65 
      34  -20   1 -10 3.50 
 
Frontal Lobe 
Inferior Frontal Gyrus   45  -53 27   2 3.06 
        -44 30 17 3.15 
      46  -55 35   9 2.83 
      47  -40 29       -10 3.42 
 
Middle Frontal Gyrus    9  -55 27 27 3.81 
      46  -48 48 18 2.82 
 
Superior Frontal Gyrus   10  -22 56 25 3.08 
 
Anterior Cingulate Gyrus   32  -14 21 30 2.67 
 
 
The location of the activation peaks are located with reference to the Talaraich und Tourneaux stereotaxic template. The 
coordinates  x+ are located in the right hemisphere. The coordinates y+ are located anterior to the anterior comisure, and the 
coordinates z+ are located superior to the AC-PC plane. 
The distances are given in mm. 
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Table 13. Peaks of significantly Higher Activation for Location Matching compared to 
Object Matching in the Healthy Control Subjects. 
 
 
RIGHT HEMISPHERE 
 
Region    Brodmann Area x y z Zvalue 
Occipital Lobe 
Occipital Gyrus                                         19                       28        -76      28        3.63 
 
Parietal Lobe 
Precuneus             7   10 -47 61 4.34 
        14 -68 49 4.62 
 
 
LEFT HEMISPHERE 
 
Region    Brodmann Area x y z Zvalue 
Parietal Lobe 
Precuneus                                                    7                       -10       -64      47          4.38 
     
Superior Parietal Lobulus                           7                         -6       -68      55           4.50 
 
 
The location of the activation peaks are located with reference to the Talaraich und Tourneaux stereotaxic template. The 
coordinates  x+ are located in the right hemisphere. The coordinates y+ are located anterior to the anterior comisure, and the 
coordinates z+ are located superior to the AC-PC plane. 
The distances are given in mm. 
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Table 14.  Peaks of Significantly Higher Activation in MCI compared to HC during 
Location Matching Task 
 
RIGHT HEMISPHERE 
 
Region    Brodmann Area x y z Zvalue 
Frontal Lobe 
Medial Frontal Gyrus    8  2 45 42 2.75 
      9  0 58 27 3.30 
      10  4 61 14 2.69 
 
LEFT HEMISPHERE 
 
Region    Brodmann Area x y z Zvalue 
 
Frontal Lobe 
Inferior Frontal Gyrus   46  -46 46 20 3.59 
 
Middle Frontal Gyrus    46/9  -36 46 27 4.57 
      8  -34 28 47 3.34 
 
Superior Frontal Gyrus   10  -24 58 25 3.97 
      8  -18 45 38 3.90 
      8  -10 28 52 3.11 
 
Medial Frontal Gyrus     9  -57 23 34 4.04 
       9  -42 55 14 3.36 
      10   -38 64  6 3.18 
  -36  47  3 2.62 
8 -8 31 41 2.54 
9 -8 42 33 2.97 
10 -8 55  7 2.75 
 
 
 
The location of the activation peaks are located with reference to the Talaraich und Tourneaux stereotaxic template. The 
coordinates  x+ are located in the right hemisphere. The coordinates y+ are located anterior to the anterior comisure, and the 
coordinates z+ are located superior to the AC-PC plane. 
The distances are given in mm. 
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Figure 5.  Object Matching activation pattern in the Healthy Control Group   
 
 
 
 
 
The presentation of the results is divided in 24 planes of the brain. From left to right in every row, the planes are ascendant, 
and from bottom to top. 
The number in mm shows the distance to the AC-PC plane.  
The right hand side of the picture shows the left hand side of the brain, and the left hand side of the picture shows the right 
hand side of the brain. 
The activated areas are showed in red and yellow; red means activation intensities between 0.31-0.62 and yellow between 
0.62-1.0. 
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Figure 6. Object Matching activation pattern in the MCI group   
 
 
 
 
 
The presentation of the results is divided in 24 planes of the brain. From left to right in every row, the planes are ascendant, 
and from bottom to top. 
The number in mm shows the distance to the AC-PC plane.  
The right hand side of the picture shows the left hand side of the brain, and the left hand side of the picture shows the right 
hand side of the brain. 
The activated areas are showed in red and yellow; red means activation intensities between 0.31-0.62 and yellow between 
0.62-1.0. 
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Figure 7. Location Matching activation pattern in the Healthy Control Group 
 
 
 
 
        
 
 
The presentation of the results is divided in 24 planes of the brain. From left to right in every row, the planes are ascendant, 
and from bottom to top. 
The number in mm shows the distance to the AC-PC plane.  
The right hand side of the picture shows the left hand side of the brain, and the left hand side of the picture shows the right 
hand side of the brain. 
The activated areas are showed in red and yellow; red means activation intensities between 0.31-0.62 and yellow between 
0.62-1.0. 
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Figure 8. Location Matching activation pattern in the MCI group 
 
 
 
 
       
 
 
The presentation of the results is divided in 24 planes of the brain. From left to right in every row, the planes are ascendant, 
and from bottom to top. 
The number in mm shows the distance to the AC-PC plane.  
The right hand side of the picture shows the left hand side of the brain, and the left hand side of the picture shows the right 
hand side of the brain. 
The activated areas are showed in red and yellow; red means activation intensities between 0.31-0.62 and yellow between 
0.62-1.0. 
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Figure 9. The contrast Face matching versus Location Matching and Location Matching 
versus Face matching in the Healthy Controls 
 
 
 
 
 
 
 
 
 
The presentation of the results is three dimensional. In the first row are shown the activated areas for the contrast face 
matching > location matching, on the left hand side left hemisphere, on the right hand side right hemisphere. In the second 
row are shown the results for the contrast location matching > face matching, on the left hand side left hemisphere, on the 
right hand side right hemisphere. 
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Figure 10. Location Matching activation patterns for the contrast MCI > HC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The presentation of the results is divided in 24 planes of the brain. From left to right in every row, the planes are ascendant, 
and from bottom to top. 
The number in mm shows the distance to the AC-PC plane.  
The right hand side of the picture shows the left hand side of the brain, and the left hand side of the picture shows the right 
hand side of the brain. 
The activated areas are showed in red and yellow; red means activation intensities between 0.31-0.62 and yellow between 
0.62-1.0. 
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9. DISCUSSION  
9.1. Discussion of the Method 
Challenges of fMRI  
 Functional MRI is a powerful method for investigating brain function but it is also a 
challenging method that needs to be utilized appropriately (Savoy, 2005). For appropriate use 
it is necessary to have knowledge of different areas: 
• physics and engineering underlying the imaging device 
• temporal and spatial properties of the hemodynamic response that we measure 
using fMRI 
• functional and structural anatomy of the human brain 
• the analysis steps which conduct from a collection of MR data to a statistically 
map of brain activation 
• the way all these factors interact by interpreting the results obtained 
 In spite of the difficulty, research using fMRI is growing very fast. The power of the 
method is based on the analysis of many different brain images to see the differences between 
brain states (or between population groups). The results obtained with this method are very 
reliable.  
 
Advantages and limitations of fMRI  
 FMRI has great advantages as a method of functional neuroimaging comparing to 
others. It is indeed a powerful and flexible tool, but it has also some experimental 
weaknesses.  
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 FMRI was the first technology that promised non-invasive, high spatial resolution, 
volumetric images of brain activity in normal human subjects, with the opportunity to do 
repeated studies on the same subject. It is due to the advantages of the method: 
-Potential for high temporal and spatial resolution. The spatial resolution allows us to find 
changes in a map across different spatial localisations, and the temporal resolution allows 
finding changes at a single location over the time. Neuroscience techniques differ in their 
spatial and temporal resolution, for example EEG and MEG have a very good temporal 
resolution, but the spatial resolution is poor. PET techniques has not such a good balance 
between temporal and spatial resolution like fMRT. 
-Lack of radioactivity: the magnetic field does not produce any kind of adversary effects, so 
the experiments can be repeated multiple times on the same subject. SPECT and PET give 
excellent functional results as well, but carry the burden of radiation. 
-Non invasive technology, there are no secondary effects for the subjects.  
-Can be performed on increasingly common state-of-the art MRI scanners 
 The experimental weaknesses of the method are associated with its disadvantages: 
-Extreme sensitivity to head movement. Head movement produce distortion in the results, 
which are obtained from the scanner. It is very important that the subjects do not move while 
performing the scanning. Thousands of images are collected during the scanning and it is 
necessary that they are aligned. Most of the young people scans do not show head movement. 
It can turn difficult for older people, to lie quite for longer time so that not all the data from 
scanned subjects can be used. In particular with MCI subjects the percent of data which could 
not be used because of head movement was very high. We carried out scanning of more than 
30 MCI Patients, but we could only include the data from 16 of them because of the artefacts 
which were present in the data. 
-There are some contraindications, where it is not possible at all to perform fMRI: the 
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presence of irremovable magnetic devices (like pacemaker, metal implantation, tattoos, 
permanent make-up, etc.), pregnancy and susceptibility to extreme claustrophobia. Subjects 
with these characteristics can not be scanned.  
 
Safety considerations 
 FMRI is a very safe method but it has also some risks. Bringing a magnetic object 
inside the room, in which the scanner is situated, can have disastrous consequences. The 
magnetic field has a very strong gradient near the scanner, and every kind of magnetic object 
could be “pulled” into the scanner. 
 The high-speed sequences which are used for fMRI studies generate a great acoustical 
noise. The subjects need to use earplugs, to not suffer some damage in the ears. 
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9.2. Discussion of the Results 
9.2.1 The Healthy Control Group 
Object Matching in the Healthy Controls 
 The HC group activated for the object matching task (Table 8, Figure 5) in the right 
hemisphere the Fusiform Gyrus and Precuneus (Occipital Lobe), Inferior Parietal Lobe, 
Inferior and Middle Frontal Gyrus, and Anterior Cingulate Gyrus (Frontal Lobe).  In left 
hemisphere, they activated areas located in the Inferior Occipital Gyrus and Fusiform Gyrus 
(Occipital Lobe), as well as in the Inferior Frontal Gyrus. 
 The activation found involves some of the areas of the ventral pathway for the object 
matching task, and they are in concordance with the results from Ungerleider, Mishkin, 
Haxby and collegues (Ungerleider and Mishkin, 1982; Ungerleider and Desimone, 1986a; 
Ungerleider and Desimone, 1986b; Ungerleider and Haxby, 1994). Very interesting in our 
results is the fact that beside the activation of some of the areas of the ventral pathway we 
also found activation in the Fusiform Gyrus in the right and in the left hemisphere. The PET 
study from  Haxby and Collegues (Haxby et al., 1994) had a similar design to ours, with a 
face matching task and a location matching task in a group of healthy young people. They 
measured changes in regional cerebral blood flow associated to the perception of faces and 
locations. They found strong activation in the Fusiform Gyrus during the face matching task 
as well. This area is responsible for face recognition; it allows the perception of the face as a 
unique entity. In their conclusion Haxby and colleagues argued that there is lack of activation 
of more anterior temporal cortices associated with the face matching task, because the 
Fusiform Gyrus is more involved in this object recognition. The face matching task is a 
special kind of object matching task (Sergent et al., 1992), where the objects to be recognized 
are faces. It seems that the ventral pathway in this case has less activation in the temporal 
lobe and instead there is a strong activation in the Fusiform Gyrus. Our results for the HC 
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group are consistent with those from Haxby and colleagues. 
 
Location Matching in the Healthy Controls 
 The HC group activated for the location matching task (Table 9, Figure 7) areas in the 
right hemisphere that were located in the Middle Occipital Gyrus and Precuneus (Occipital 
Lobe), in the Inferior Parietal Lobe (Parietal Lobe), and  in the Inferior Frontal Gyrus 
(Frontal Lobe).  In the left hemisphere the activation peaks were found in the Inferior and 
Middle Occipital Gyrus, and Precuneus (Occipital Lobe), in the Inferior Parietal Lobulus 
(Parietal Lobe).   
 According to the results of Haxby and collegues (Haxby et al., 1994), we found 
activated areas in the location matching task which belong to the dorsal pathway.  
  
 
The contrast Object Matching versus Location Matching in the Healthy Controls 
 Comparison between the object and location matching tasks showed that the activated 
regions in the visual system varied depending on the task they performed.  
 In the contrast object matching versus location matching (Table 12, Figure 9) there 
were activations found in the right hemisphere in Cuneus, Lingual Gyrus, Inferior Occipital 
Gyrus and Fusiform Gyrus; in the Inferior and Superior Temporal Gyrus; in the Medial, 
Inferior and Superior Frontal Gyrus, as well as the Anterior Cingulate Gyrus. In the left 
hemisphere the activations found were located in the Lingual Gyrus, in the Parahippocampal, 
and in the Inferior, Middle and Superior Frontal Gyrus, as well as in the Anterior Cingulate 
Gyrus.    
 In the object matching task they had to attend to the characteristics of the object, so 
there was more activation in the parvocellular dominated ventral pathway. These results are 
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consistent with those of  Corbetta and Haxby and collegues (Corbetta et al., 1991a; Corbetta 
et al., 1991b; Haxby et al., 1991; Haxby et al., 1994); they showed that the attention to one 
specific aspect of  a visual stimulus increases selectively activation for the network that 
processes the specific type of stimulus. Corbetta et al. (Corbetta et al., 1991a) showed that the 
neural systems involved in discriminating between the shape, color and speed of a visual 
stimulus involves different regions of the extrastriate cortex depending on the selected feature 
processed. In a similar form, Haxby et al. (Haxby et al., 1994) showed that the selective 
attention to faces is associated with increased activity in those cortical areas that process the 
attended information, it means ventral pathway for object matching. 
 Our results are consistent with those from Haxby and Corbetta, for the selectively 
activation of the visual system depending on the test performed. So in this case the stronger 
activation due to object matching in contrast with location matching in healthy controls 
shows selective activation in the ventral pathway (parvocellular).  
 We also found increased activation of frontal cortical areas during face matching than 
during location matching tasks. This findings are consistent with the data from Grady et al. 
(Grady et al., 1994), which showed greater activation of frontal areas during a face and a 
location matching task in older adults as compared to young adults. It has been suggested that 
greater engagement of frontal areas in older (healthy) adults indicate that there is an age-
related increase in the reliance on frontally-mediated strategic monitoring of low-level 
processes (Anderson and Grady, 2004; Grady et al., 1994). Our results show the effects of 
normal aging in the healthy group, consistent with the data from Grady and colleagues of 
age-realted differences in face processing (Grady, 2002), where they found that an increased 
prefrontal activity in old healthy adults is a more general response to increased cognitive 
effort or need for resources. 
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The contrast Location Matching versus Object Matching in the Healthy Controls 
 This contrast shows activations due to the location matching task in comparison with 
the face matching task. It was showed again that the activated regions in the visual system 
varied depending on the task they performed. 
 In the contrast location matching versus face matching (Table 13, Figure 9) the 
activations found were located in the right hemisphere in the occipital lobe. In the left 
hemisphere the activation was located in the Superior Parietal Lobulus. In Precuneus the 
activation was bilateral. 
 In the location matching task they had to attend to the spatial location of the objects; 
that produced activation along the magnocellular dominated dorsal pathway. These results 
are consistent with those of  Corbetta and Haxby again (Corbetta et al., 1991a; Corbetta et al., 
1991b; Haxby et al., 1991; Haxby et al., 1994).   Haxby et al. (Haxby et al., 1994) showed 
that the selective attention to locations is associated with increased activity in those cortical 
areas that process the attended information, it means dorsal pathway for location matching.  
  When the subjects performed the location matching task compared to the face 
matching task, they showed regions of higher activation within the dorsal visual pathway 
(magnocellular). In this case, we did not find increase activation of frontal cortical areas in 
the location matching task compared to the face matching task. According with the results 
from Grady (Grady, 2002), face processing in older adults requires more effort than young 
people. This effect seems not to appear in the location matching task. 
 
9.2.2. The Mild Cognitive Impaired Group 
Object Matching in the MCI Group 
 The activated areas while performing face matching for the MCI group (Table 10 and 
Figure 6) were found in the right hemisphere in the Inferior Occipital Lobe and Fusiform 
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Gyrus, in the Inferior Temporal Gyrus, Inferior Parietal Lobulus, in the Inferior and Middle 
Frontal Gyrus; and in the left hemisphere, the activation in the Occipital Lobe took place in 
the Inferior and Middle Occipital Lobe, and in the Frontal Lobe in the Inferior Frontal Gyrus.  
 We see here again strong activation of the Fusiform Gyrus. Frontal areas are activated 
as well. The differences between this activation pattern and the one of the old healthy group 
are determined by activation of the areas which belong to the dorsal pathway and to the 
ventral pathway. It means that the subjects were using some areas of the magnocellular 
pathway of the visual system while performing an object matching task.  
 
Location Matching in the MCI Group 
 The network of activated areas while performing the location matching task for the 
MCI group (Table 11 and Figure 8),  were found in the right hemisphere in Precuneus, 
Middle Occipital Gyrus, in the Superior Parietal Lobulus, and in the Inferior Frontal Gyrus. 
In the left hemisphere the activation took place in the Precuneus and Occipital Gyrus, in the 
Hippocampal Gyrus, in the Superior Parietal Lobulus, and in the Inferior, Middle and Frontal 
Gyrus. 
 Like in the face matching task the MCI group recruited for the location matching task 
not only areas from the dorsal pathway but also some areas from the ventral pathway. It 
means that the subjects were using some areas of the parvocellular pathway of the ventral 
system while performing a location matching task.  
 During the location matching task the MCI group recruited also frontal areas, in 
contrast to the HC. It would mean for the MCI group the need of higher activation areas to 
perform the task. 
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The contrast Object Matching versus Location Matching 
 Within the MCI group there were no regions that were more activated in the face 
matching task compared to the location matching task. 
  As shown in the activation pattern of the MCI group for face matching, together with 
ventral areas, there were some areas of the dorsal pathway activated while performing the 
face matching task, so that there was no selective activation of the ventral pathway for 
performing the task. In the contrast object matching versus location matching, it is shown the 
lack of selectivity in the activation of the parvocellular pathway of the visual system.  
 
 The contrast Location Matching versus Object Matching 
 Within the MCI group there were no regions that were more activated in the location 
matching task compared to the face matching task. 
 It is also shown in the activation pattern of the MCI group for location matching, that 
some areas of the ventral pathway were activated while performing the location matching 
task, so that in this case a lack of selective activation of the dorsal pathway was also present.  
 
No selective activation of the Visual System in Mild Cognitive Impaired Subjects 
 Unlike the HC group, the MCI group did not selectively activate the dorsal and ventral 
attention pathways; MCI showed activation of some regions of both of the pathways in every 
task, as indicated in Tables 11 and 12 and Figures 6 and 8. In addition, the contrast 
comparing object matching to location matching did not show any regions of greater 
activation for one task compared to the other task.  
 It seemed that in the MCI group both pathways were activated irrespective of the 
visual task. One explanation for these findings could be that the subjects were attending to 
relevant and irrelevant information during the task; it means that they were attending to the 
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spatial information and characteristics of the objects at the same time. But the fact is that the 
performance of the task and the response time for both groups did not show statistically 
differences. Both groups performed the task, but the network recruited was different for the 
MCI group.  
 There are different hypotheses as to why there was no selective activation of the visual 
pathways during the tasks. One reason may be that the MCI group was recruiting regions 
along both pathways as a compensatory strategy for performing the task. Another hypothesis 
is that the subjects were performing the task using a different strategy, which led to activation 
in both pathways. The last possibility is that MCI subjects used a similar strategy as the HC 
group but they invoked a different neural network for performing the task. 
 The lack of selective activation in the face and location matching tasks (as shown by 
the HC) would indicate that the underpinning neuropathology (even in preclinical stages) has 
an effect on the areas activated for performing a task.  
 The finding that there was no frontal activation in the contrast face matching versus 
location matching in MCI patients is very interesting because it seems to be somewhat 
unexpected taking in mind the results for the contrast object matching versus location 
matching for HC. But this result might indeed reflect the fact that the frontal areas as 
compensatory strategy are more recruited during location matching in MCI patients than in 
HC maybe because the dorsal pathway necessary for location matching is more susceptible 
for early subclinical impairment in MCI. Thereby a greater activation of frontal areas in the 
contrast face matching versus location matching as shown before for older adults is not 
longer visible. 
 
 84 
9.2.3. MCI subjects compared to Healthy controls 
Face Matching Task activation in MCI subjects compared to Healthy Controls 
  In this contrast, we wanted to examine if the activation in the MCI group was different 
compared to the HC group. We expected that a higher activation in the ventral pathway in the 
MCI group would indicate a compensatory process of the group. 
 When we made the contrast of the activation of the face matching task between the 
MCI group and the HC group, we found no areas that had statistically significant higher 
activation in the MCI group compared to the HC group. 
 These results are consistent with those from Sperling et al. (Sperling et al., 2003), 
where no differences in extrastriate activity between mild AD patients and age-matched 
control participants on a task of face name encoding.  
 
Location Matching Task activation in MCI subjects compared to Healthy Controls 
 We found that there was increased activation in the dorsal pathway in the MCI group 
compared to the HC group in the location matching task. The activation peaks (table 14 and 
Figure 10) for the contrast MCI versus HC in the location matching task were found in the 
Medial Frontal Gyrus bilateral. In addition in the left hemisphere activation peaks were found 
in the Inferior, Middle and Superior Frontal Gyrus. 
  In addition to non-selective activation of the pathways, the differences that we found 
between groups were increased activation in the frontal lobes in performing the location 
matching task (Table 14 and Figure 10). We did find increased frontal activity in the contrast 
face versus location matching for HC but did not find such a difference for MCI. This fits 
into the picture that there was a stronger frontal activation pattern in the contrast MCI versus 
HC for location object matching because of the impairment of the dorsal pathway due to the 
pathology. Frontal areas in location matching tasks may have been activated more as a 
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compensatory mechanism by MCI patients. This finding would be consistent with the study 
from Pfefferbaum et al. (Pfefferbaum et al., 2001).  In this study a group of alcoholics were 
studied, and they showed a recruitment of activation in the dorsal pathway and increased 
activation in the frontal lobes during a visuo-spatial working memory task despite 
equivalence in behavioural performance as a compensatory mechanism. In the same way, in 
our study the MCI group may need to compensate for inefficient or altered processing in 
earlier regions along the dorsal pathway by additional neural regions in the frontal lobe.  
 The compensatory process could have involved various processes: (a) inefficient 
processing along the occipital-parietal regions, (b) MCI subject use a different strategy, (c) 
MCI subjects use the same strategy but recruited different brain regions, (d) the MCI subjects 
were attending to information non-germane to the task. Even though it was activation in the 
dorsal pathway, the recruitment of the Frontal Lobe for processing the data indicates that the 
processing of the stimuli was inefficient compared to HC. Other possibility is the utilization 
of a different strategy to perform the task. The fact that Frontal Lobe areas were recruited 
may indicate that the patients needed higher order functions to solve the task. For example, it 
would have been possible, that patients used a verbal strategy to perform the task, but we 
found no activation in Wernicke’s area. The lack of selective activation along the ventral and 
dorsal pathways suggest the possibility that the MCI group was not selectively attending to 
the germane information needed to perform the task, but overall task performance was 
equivalent in both groups. 
 The hypothesis that increased activation in the Frontal Lobe in the MCI group occurs 
as a compensatory process for the dysfunction from the dorsal pathway is supported by the 
fact that compensatory processes are not only present in patient populations but also in 
groups of cognitively normal subjects that have a high risk for AD. Smith et al. (Smith et al., 
1999) found in a group of women with a high risk for developing AD, that the activation 
patterns using fMRI for a visual naming and letter fluency task were different than in the 
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control group, although their performances were identical. Decreased activation along the 
Inferior Temporal cortex but increased activation in Left Parietal Lobe was found. This may 
be a consequence of the presence of subclinical neuropathology. Bookheimer et 
al.(Bookheimer et al., 2000) studied a group of 30 subject who were carriers of the APOE 
epsilon4 (high risk group) allele and APOE epsilon3 allele (low risk group). The activation 
patterns using fMRI were determined while subjects memorized and recalled unrelated pairs 
of words. The patterns found were different for both groups, a network comprising of the 
Parietal and Frontal Lobe, and hippocampus had higher activation in the high risk group 
compared to the low risk group. So the differences were depending on the genetic risk of 
Alzheimer’s disease and may predict a decline in memory. The functional re-organization as 
shown in these studies is heterogeneous with respect to the functional changes dependent on 
the cognitive paradigm, the risk group, the severity of the disease, and the various possible 
mechanisms that exist as a compensatory mechanism. 
 
Magnocellular Deficit Hypothesis 
 The activation pattern that we found in our study was increased activation in the 
Frontal Lobe in the MCI group for the location matching task compared to the HC group and 
no differences in activation between groups for the object matching task. This would support 
the hypothesis that the magnocellular dominated pathway has increased susceptibility to 
neurodegenerative damage than the ventral pathway.  
 Sadun may have been the first to suggest that AD may involve a deficit in the 
magnocellular pathway neural system (Sadun, 1989). But there are other studies in which 
deficits in the magnocellular but also parvocellular pathway were shown (Cronin-Golomb et 
al., 1991; Rizzo et al., 2000b; Rizzo et al., 2000a). One suggestion is that the deficits may be 
expressed more strongly in some patients, indicating that it may be some subtypes of AD 
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with vivid visual problems. One example would be the AD patients presenting a major 
impairment of visuospatial skills referred to as Balint's syndrome. Mendez found significant 
hypometabolism in the posterior dorsal visual stream in AD patients with Balint’s Syndrom 
compared to both without Balint’s syndrome and to HC (Mendez et al., 1990). Hof and 
colleagues found by the evaluation of a large autopsy population of brains that the visual 
areas of the occipital and posterior parietal regions were more damage than temporal and 
prefrontal cortex (Hof et al., 1990a). The present study did not have any patients with 
Balint’s syndrome. 
 In the same way, Mentis et al.(Mentis et al., 1996; Mentis et al., 1998) showed the 
abnormal visual cortical function in AD patients as an expression of the impairment of the 
magnocellular visual system. Our work extends these results to a group of MCI subjects 
using a cognitive task that selectively activates either visual pathway in HC. Comparing the 
activation patterns within both groups of subjects for both tasks (object and location 
matching tasks), we could show the differences in impairment of the pathways for the MCI 
group. 
 Our results show more impairment of the magnocellular pathway than the 
parvocellular in our MCI group. It would indicate that the visual dysfunction already occurs 
in such early stadium of the disease, and could be used as a diagnostic feature for a 
preclinical diagnosis. Because visual deficits of AD patients are typically undiagnosed, it 
would be necessary to pay more attention to these kinds of deficits, because these symptoms 
have profound effects on the ability of the patients to interact with their environment. It is 
likely that the differences in brain activity seen in older adults and in MCI subjects (as well 
as it is shown in other studies with AD patients) develop gradually over time, but it is not 
known at what point these changes begin. Finally the relation between activation differences 
in visual and prefrontal regions, or other brain areas, is not known (Anderson and Grady, 
2004). 
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Further work on the determination of visual dysfunction in aging as well as people at risk for 
AD and MCI, and how these changes are expressed in terms of cognitive difficulties, would 
be a way to better understand this disease. 
 
9.1.4. Hemodynamic Response Function 
 The passive stimulus task was a control experiment to assess if the two groups had a 
difference in the BOLD signal magnitude in response to a stimulus. Lack of differences 
between groups indicate that the differences in the activation patterns for the object and 
location matching task within the groups is not due to a global difference in BOLD 
magnitude between groups. Thus the increased activation in the location matching task in the 
MCI group compared to HC group is due to the cognitive task and not to non-specific 
difference of the BOLD signal.  
 The difference in activation in the location matching task between groups is unlikely 
due to brain atrophy. The areas of increased activation of the MCI group compared to the HC 
group were in the Frontal Lobes. If grey matter atrophy had affected our results, we would 
have expected the MCI group to have had lower activation in parietal end temporal areas 
compared to the HC. 
 
9.1.5. Heterogeneousness of the MCI group 
 Even thought the initial diagnosis of the MCI group was limited to a single memory 
dysfunction the group of participants in the study was probably a heterogeneous group 
composed of:  
• those who will convert to AD in the future 
• those who may convert to other types of dementia or neurodegenerative 
syndromes that cause cognitive dysfunction 
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• those that may remain classified as MCI 
 Based on previous studies it can be expected that between 50 to 80 % will convert to 
AD in 5 years (Petersen et al., 1999; Geslani et al., 2005). If the subjects would be followed 
in the clinical development, it could be possible to better elucidate in the future the difference 
in activation between those MCI subjects that convert to AD and those that convert to other 
neurological or psychiatric diseases and those subjects that do not suffer cognitive decline. 
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10. CONCLUSIONS 
 The results show that the HC group selectively activated the ventral pathways for the 
object matching task and the dorsal pathway for the location matching task. In contrast, the 
MCI subjects did not show selective activation along the ventral and dorsal pathways, and 
they had higher activation in the left frontal lobe compared to the HC when performing the 
location matching task. The HC group did not show areas of significantly greater activation 
compared to the MCI group in any task. Changes in the neural substrate underpinning visual 
attention function in the comparison between both groups are detailed within both visual 
pathways. 
 This work identifies abnormalities in the visual system in both visual pathways in MCI 
subjects consistent with previous reports of visual attention abnormalities in AD patients. The 
present results using the visual tasks suggest that even when behavioural performance 
between groups is the same, the neural systems that support performance may differ. The 
differences in activation pattern that we found may happen when the ideal network (as 
defined by the healthy control group) is compromised by disease. This may occur so long the 
brain is able to compensate for the impairment suffered. In the case of the MCI subjects the 
compensatory mechanism helps the subjects to maintain the performance as well as in HC.  
 It has already been shown that AD involves also a processing disorder  in the visual 
sensory pathways. This pathological property of the illness exacerbates memory symptoms 
(hallmark of the disease). The results from our study extended the results from previous 
studies with AD patients to a group of MCI patients. In addition, it extended the results by 
utilizing cognitive tasks that activated selectively either visual pathway in HC. 
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 Visual deficits of AD patients are typically undiagnosed. Mild or subclinical changes 
in performance may go undetected unless brain imaging techniques are used to measure brain 
activation during performance of the task. This demonstrates the usability of brain imaging 
techniques to better understand the underlying pathology of AD and to better differentiate 
subtypes of MCI.  
To better understand the changes occurring within the visual cortex in the process of 
AD, it would be necessary to follow up the MCI group, investigating which of the subjects 
have develop a mild AD. Following the clinical development of the subjects will allow us to 
better elucidate in the future the difference in activation among those MCI subjects that 
convert to AD and those that convert to other neurological or psychiatric diseases, and those 
subjects that do not suffer cognitive decline. This would further illuminate the changes along 
the ventral and dorsal pathways due to AD. 
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